

Clinical Pharmacokinetics of Mycophenolate Mofetil

Clinical Pharmacokinetics

34, 429-455

DOI: 10.2165/00003088-199834060-00002

Citation Report

#	ARTICLE	IF	CITATIONS
1	PAH extraction and estimation of plasma flow in human postischemic acute renal failure. American Journal of Physiology - Renal Physiology, 1999, 277, F312-F318.	1.3	36
2	Identification of a Pharmacologically Active Metabolite of Mycophenolic Acid in Plasma of Transplant Recipients Treated with Mycophenolate Mofetil. Clinical Chemistry, 1999, 45, 419-422.	1.5	140
4	Therapeutic drug monitoring of immunosuppressant drugs. British Journal of Clinical Pharmacology, 1999, 47, 339-350.	1.1	65
5	Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. British Journal of Pharmacology, 1999, 126, 1075-1082.	2.7	189
6	The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clinical Pharmacology and Therapeutics, 1999, 66, 492-500.	2.3	123
7	Mycophenolate Mofetil. BioDrugs, 1999, 12, 363-410.	2.2	38
8	Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transplantation Proceedings, 1999, 31, 1135-1137.	0.3	63
9	Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrology Dialysis Transplantation, 1999, 14, 2710-2713.	0.4	42
10	Advancing the art of immunosuppression with the science of pharmacology. Current Opinion in Organ Transplantation, 2000, 5, 255-262.	0.8	6
11	Evaluation of Limited Sampling Strategies for Estimation of 12-Hour Mycophenolic Acid Area Under the Plasma Concentration-Time Curve in Adult Renal Transplant Patients. Therapeutic Drug Monitoring, 2000, 22, 549-554.	1.0	55
12	Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?. Clinical Biochemistry, 2000, 33, 107-113.	0.8	141
13	Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. Journal of the European Academy of Dermatology and Venereology, 2000, 14, 187-190.	1.3	42
14	Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clinical Transplantation, 2000, 14, 179-188.	0.8	68
15	The structure of inosine 5- α -monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology, 2000, 47, 163-184.	2.0	192
16	Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clinical Biochemistry, 2000, 33, 203-208.	0.8	26
17	Quantification of free mycophenolic acid by high-performance liquid chromatography-atmospheric pressure chemical ionisation tandem mass spectrometry. Biomedical Applications, 2000, 748, 151-156.	1.7	34
18	Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Transplant International, 2000, 13, S301-S305.	0.8	18
19	Treatment of a Myasthenic Dog with Mycophenolate Mofetil. Journal of Veterinary Emergency and Critical Care, 2000, 10, 177-187.	0.4	16

#	ARTICLE	IF	CITATIONS
20	Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. <i>Transplant International</i> , 2000, 13, S301-S305.	0.8	23
21	Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. <i>Pediatric Nephrology</i> , 2000, 14, 95-99.	0.9	51
22	Determination of the Acyl Glucuronide Metabolite of Mycophenolic Acid in Human Plasma by HPLC and Emit. <i>Clinical Chemistry</i> , 2000, 46, 365-372.	1.5	149
23	Mycophenolic acid concentrations are associated with cardiac allograft rejection. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 1071-1076.	0.3	74
24	Pharmacokinetic study of mycophenolate mofetil in Asian renal transplant recipients. <i>Transplantation Proceedings</i> , 2000, 32, 1753-1754.	0.3	5
25	Pharmacokinetics of mycophenolate mofetil in eight pediatric renal transplant patients. <i>Transplantation Proceedings</i> , 2000, 32, 388-390.	0.3	7
26	Mycophenolic Acid: A One Hundred Year Odyssey from Antibiotic to Immunosuppressant. <i>Chemical Reviews</i> , 2000, 100, 3801-3826.	23.0	258
27	Drug Concentration Monitoring of Immunosuppressive Agents. <i>BioDrugs</i> , 2000, 14, 355-369.	2.2	15
28	Determination of plasma mycophenolic acid using the Emit® immunoassay in a Cobas Fara II centrifugal analyzer. <i>Immuno-Analyse Et Biologie Specialisee</i> , 2001, 16, 415-418.	0.0	0
29	Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 1035-1043.	0.3	38
30	Monitoring of mycophenolic acid in pediatric renal transplant recipients. <i>Transplantation Proceedings</i> , 2001, 33, 1040-1043.	0.3	19
31	The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. <i>Transplantation Proceedings</i> , 2001, 33, 1080-1081.	0.3	93
32	Therapeutic drug monitoring - is it important for newer immunosuppressive agents?. <i>Drugs and Therapy Perspectives</i> , 2001, 17, 8-12.	0.3	1
33	Quantification of Mycophenolic Acid in Plasma Samples Collected during and Immediately after Intravenous Administration of Mycophenolate Mofetil. <i>Clinical Chemistry</i> , 2001, 47, 1485-1488.	1.5	21
34	Current Issues in Therapeutic Drug Monitoring of Mycophenolic Acid: Report of a Roundtable Discussion. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 305-315.	1.0	239
35	Effect of Cyclosporine on Mycophenolic Acid Area Under the Concentration-Time Curve in Pediatric Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 514-519.	1.0	58
36	Comparison of the Effects of Tacrolimus and Cyclosporine on the Pharmacokinetics of Mycophenolic Acid. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 119-128.	1.0	293
37	MYCOPHENOLATE MOFETIL IMPAIRS HEALING OF LEFT-SIDED COLON ANASTOMOSES 1. <i>Transplantation</i> , 2001, 71, 1429-1435.	0.5	42

#	ARTICLE	IF	CITATIONS
38	Determination of mycophenolic acid and its phenol glucuronide metabolite in human plasma and urine by high-performance liquid chromatography. <i>Biomedical Applications</i> , 2001, 763, 35-45.	1.7	40
39	Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. <i>Clinical Transplantation</i> , 2001, 15, 176-184.	0.8	38
40	Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. <i>Clinical Transplantation</i> , 2001, 15, 402-409.	0.8	75
41	Mycophenolate mofetil in pediatric heart transplant recipients: A single-center experience. <i>Pediatric Transplantation</i> , 2001, 5, 112-118.	0.5	42
42	The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 605-609.	1.1	93
43	Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. <i>Clinical Biochemistry</i> , 2001, 34, 17-22.	0.8	107
44	The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. <i>Liver Transplantation</i> , 2001, 7, 739-742.	1.3	30
45	Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. <i>British Journal of Pharmacology</i> , 2001, 132, 1027-1034.	2.7	140
46	The anti-herpesvirus activity of (1S,2R)-9-[[1-bis(hydroxymethyl)cycloprop-1-yl]methyl]guanine is markedly potentiated by the immunosuppressive agent mycophenolate mofetil. <i>Antiviral Research</i> , 2001, 49, 121-127.	1.9	12
47	Immunosuppressive Drugs and Novel Strategies to Prevent Acute and Chronic Allograft Rejection. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2001, 22, 559-580.	0.8	11
48	The Impact of Novel Immunosuppressive Agents on Infections in Organ Transplant Recipients and the Interactions of These Agents with Antimicrobials. <i>Clinical Infectious Diseases</i> , 2002, 35, 53-61.	2.9	78
49	Monitoring of Mycophenolic Acid in Clinical Transplantation. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 68-73.	1.0	40
50	International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on Immunosuppressive Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 59-67.	1.0	82
51	Atypical Pharmacokinetics and Metabolism of Mycophenolic Acid in a Young Kidney Transplant Recipient With Impaired Renal Function. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 438-443.	1.0	7
52	Disappearance of measurable mycophenolate mofetil (Cell Cept®) in a patient with a renal transplant and an ileostomy. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 318-319.	0.4	2
53	Impairment of Mycophenolate Mofetil Absorption by Calcium Polycarbophil. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 1275-1280.	1.0	23
54	Monitoring mycophenolic acid. <i>Annals of Clinical Biochemistry</i> , 2002, 39, 173-183.	0.8	55
55	Mycophenolate Mofetil: Selective T Cell Inhibition. <i>American Journal of the Medical Sciences</i> , 2002, 323, 194-196.	0.4	23

#	ARTICLE	IF	CITATIONS
56	Pharmacokinetics and Protein Binding of Mycophenolic Acid in Stable Lung Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 310-314.	1.0	35
57	Pharmacokinetics and Protein Adduct Formation of the Pharmacologically Active Acyl Glucuronide Metabolite of Mycophenolic Acid in Pediatric Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 390-399.	1.0	93
58	Immunosuppressive Therapy for Paediatric Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2002, 41, 115-135.	1.6	74
59	Therapeutic Monitoring of Mycophenolate Mofetil in Organ Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2002, 41, 319-327.	1.6	33
60	Enterohepatic Circulation. <i>Clinical Pharmacokinetics</i> , 2002, 41, 751-790.	1.6	521
61	Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus. <i>Clinical Pharmacokinetics</i> , 2002, 41, 813-851.	1.6	272
62	Influence of Ferrous Sulfate on the Solubility, Partition Coefficient, and Stability of Mycophenolic Acid and the Ester Mycophenolate Mofetil. <i>Drug Development and Industrial Pharmacy</i> , 2002, 28, 1275-1283.	0.9	29
63	Use of mycophenolate mofetil in patients with transplanted heart and renal insufficiency: the relevance of the pharmacokinetic study. <i>Transplantation Proceedings</i> , 2002, 34, 144-145.	0.3	8
64	Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy. <i>Transplantation Proceedings</i> , 2002, 34, 1745-1747.	0.3	10
65	Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. <i>Transplantation Proceedings</i> , 2002, 34, 2922-2924.	0.3	28
66	Pharmacodynamics of Mycophenolate Mofetil after Heart Transplantation: New Mechanisms of Action and Correlations with Histologic Severity of Graft Rejection. <i>American Journal of Transplantation</i> , 2002, 2, 719-732.	2.6	56
67	Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection. <i>Clinical Transplantation</i> , 2002, 16, 196-201.	0.8	20
68	Influence of mycophenolic acid and tacrolimus on homocysteine metabolism. <i>Kidney International</i> , 2002, 61, 1894-1898.	2.6	10
69	Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. <i>Kidney International</i> , 2002, 62, 1060-1067.	2.6	214
70	Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. <i>Bone Marrow Transplantation</i> , 2002, 30, 287-295.	1.3	80
71	Short-term treatment with mycophenolic acid increases bile flow in continuously perfused and cold-preserved rat livers and does not affect hepatic ischemia-reperfusion injury. <i>Transplant International</i> , 2002, 15, 265-271.	0.8	2
73	Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis. <i>Hepatology</i> , 2002, 35, 258-262.	3.6	13
74	Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. <i>Liver Transplantation</i> , 2003, 9, 383-388.	1.3	35

#	ARTICLE	IF	CITATIONS
75	Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies. <i>American Journal of Transplantation</i> , 2003, 3, 534-542.	2.6	219
76	Equivalent Pharmacokinetics of Mycophenolate Mofetil in African-American and Caucasian Male and Female Stable Renal Allograft Recipients. <i>American Journal of Transplantation</i> , 2003, 3, 1581-1586.	2.6	66
77	Measurement of free drug and clinical end-point by high-performance liquid chromatography-mass spectrometry. <i>Analytica Chimica Acta</i> , 2003, 492, 157-169.	2.6	15
78	Liquid chromatography/mass spectrometry for therapeutic drug monitoring of immunosuppressants. <i>Analytica Chimica Acta</i> , 2003, 492, 133-145.	2.6	33
79	Comparative kinetics of the uremic toxin p-cresol versus creatinine in rats with and without renal failure. <i>Kidney International</i> , 2003, 64, 1365-1373.	2.6	13
80	Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 188-197.	1.1	56
81	Outcomes in kidney transplantation. <i>Seminars in Nephrology</i> , 2003, 23, 306-316.	0.6	56
82	Mycophenolate mofetil in solid-organ transplantation. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 2325-2345.	0.9	67
83	The influence of cyclosporine on mycophenolic acid plasma concentrations: a review. <i>Transplantation Reviews</i> , 2003, 17, 158-163.	1.2	7
85	Mycophenolate Pharmacokinetics in Early Period Following Lung or Heart Transplantation. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1761-1767.	0.9	31
86	Pharmacokinetics of Mycophenolate Mofetil in Patients with Autoimmune Diseases Compared Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 721-727.	3.0	72
87	Long-Term Changes in Mycophenolic Acid Exposure in Combination with Tacrolimus and Corticosteroids Are Dose Dependent and Not Reflected by Trough Plasma Concentration: A Prospective Study in 100 De Novo Renal Allograft Recipients. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 866-880.	1.0	99
88	Twelve-Month Evaluation of the Clinical Pharmacokinetics of Total and Free Mycophenolic Acid and Its Glucuronide Metabolites in Renal Allograft Recipients on Low Dose Tacrolimus in Combination with Mycophenolate Mofetil. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 609-622.	1.0	134
89	Acyl Glucuronide Drug Metabolites: Toxicological and Analytical Implications. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 1-16.	1.0	250
90	Automated Determination of Free Mycophenolic Acid and Its Glucuronide in Plasma From Renal Allograft Recipients. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 407-414.	1.0	36
91	Frequency and severity of acute rejection in live- versus cadaveric-donor renal transplants. <i>Transplantation</i> , 2003, 76, 1452-1457.	0.5	38
92	Mycophenolate Mofetil for Solid Organ Transplantation: Does the Evidence Support the Need for Clinical Pharmacokinetic Monitoring?. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 137-157.	1.0	111
93	IN VITRO STUDY OF MYCOPHENOLIC ACID GLUCURONIDATION. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1524-1524.	1.7	6

#	ARTICLE	IF	CITATIONS
94	Review of the immunosuppressant enteric-coated mycophenolate sodium. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1333-1345.	0.9	84
95	Lack of Toxic Effects Following Acute Overdose of Cellcept (Mycophenolate Mofetil). <i>Journal of Toxicology: Clinical Toxicology</i> , 2004, 42, 917-919.	1.5	12
96	Mycophenolates in transplantation. <i>Clinical Transplantation</i> , 2004, 18, 485-492.	0.8	89
97	Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. <i>Transplant International</i> , 2004, 17, 609-616.	0.8	139
98	Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. <i>American Journal of Kidney Diseases</i> , 2004, 43, 1098-1103.	2.1	28
99	Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. <i>Proteomics</i> , 2004, 4, 2728-2738.	1.3	46
100	Monitoring trough plasma concentrations of mycophenolate mofetil in patients with uveitis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2004, 29, 53-58.	0.7	8
101	Monitoring mycophenolate in liver transplant recipients: Toward a therapeutic range. <i>Liver Transplantation</i> , 2004, 10, 492-502.	1.3	107
102	Mycophenolate mofetil monotherapy in liver transplant recipients: A single center experience. <i>Liver Transplantation</i> , 2004, 10, 1189-1194.	1.3	40
103	Development of a high pressure liquid chromatography method for the determination of mycophenolic acid and its glucuronide metabolite in small volumes of plasma from paediatric patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 35, 87-92.	1.4	25
104	HPLC determination of mycophenolic acid and mycophenolic acid glucuronide in human plasma with hybrid material. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 36, 649-651.	1.4	29
105	Quantification of free mycophenolic acid and its glucuronide metabolite in human plasma by liquid-chromatography using mass spectrometric and ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 799, 157-163.	1.2	54
106	Liquid chromatographic method for simultaneous determination of mycophenolic acid and its phenol- and acylglucuronide metabolites in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 799, 355-360.	1.2	44
107	Simple reversed-phase ion-pair liquid chromatography assay for the simultaneous determination of mycophenolic acid and its glucuronide metabolite in human plasma and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 805, 101-112.	1.2	27
108	Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 813, 287-294.	1.2	56
109	Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 434-447.	2.3	157
110	Monitoring immunosuppressive drugs. <i>Handbook of Analytical Separations</i> , 2004, , 273-296.	0.8	1
111	Treatment of Anxiety and Depression in Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2004, 43, 361-394.	1.6	68

#	ARTICLE	IF	CITATIONS
112	Evaluation of Pharmacokinetic Interactions After Oral Administration of Mycophenolate Mofetil and Valaciclovir or Aciclovir to Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2004, 43, 685-692.	1.6	44
113	Effect of Mycophenolate Mofetil on the Pharmacokinetics of Antiretroviral Drugs and on Intracellular Nucleoside Triphosphate Pools. <i>Clinical Pharmacokinetics</i> , 2004, 43, 823-832.	1.6	29
114	Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2004, 43, 253-266.	1.6	99
115	THE MAIN ROLE OF UGT1A9 IN THE HEPATIC METABOLISM OF MYCOPHENOLIC ACID AND THE EFFECTS OF NATURALLY OCCURRING VARIANTS. <i>Drug Metabolism and Disposition</i> , 2004, 32, 775-778.	1.7	192
116	Time to reach tacrolimus maximum blood concentration, mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients. <i>Clinical Therapeutics</i> , 2004, 26, 1834-1844.	1.1	12
117	Differentiation of Human Prostate Cancer PC-3 Cells Induced by Inhibitors of Inosine 5 α -Monophosphate Dehydrogenase. <i>Cancer Research</i> , 2004, 64, 9049-9056.	0.4	45
118	Dosing of Antirheumatic Drugs in Renal Disease and Dialysis. <i>Journal of Clinical Rheumatology</i> , 2004, 10, 190-204.	0.5	16
119	Interactions of Prednisolone and Other Immunosuppressants Used in Dual Treatment of Systemic Lupus Erythematosus in Lymphocyte Proliferation Assays. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1034-1045.	1.0	9
120	cDNA Microarray Analysis Reveals New Candidate Genes Possibly Linked to Side Effects Under Mycophenolate Mofetil Therapy. <i>Transplantation</i> , 2004, 78, 1145-1152.	0.5	18
121	Characterization of a Phase 1 Metabolite of Mycophenolic Acid Produced by CYP3A4/5. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 600-608.	1.0	65
122	Comparison of Liquid Chromatography-Tandem Mass Spectrometry with a Commercial Enzyme-Multiplied Immunoassay for the Determination of Plasma MPA in Renal Transplant Recipients and Consequences for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 609-619.	1.0	82
123	Using Established Immunosuppressant Therapy Effectively. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 347-351.	1.0	46
124	Determinants of Mycophenolic Acid Levels After Renal Transplantation. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 442-450.	1.0	46
125	The Rationale for and Limitations of Therapeutic Drug Monitoring for Mycophenolate Mofetil in Transplantation. <i>Transplantation</i> , 2005, 80, S244-S253.	0.5	91
126	Indications of Mycophenolate Mofetil in Liver Transplantation. <i>Transplantation</i> , 2005, 80, S142-S146.	0.5	32
127	The Influence of Norfloxacin and Metronidazole on the Disposition of Mycophenolate Mofetil. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 219-226.	1.0	70
128	From Mechanisms to Long-Term Benefits. <i>Transplantation</i> , 2005, 79, S43-S44.	0.5	15
129	Population Pharmacokinetics of Mycophenolic Acid in Kidney Transplant Pediatric and Adolescent Patients. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 378-388.	1.0	54

#	ARTICLE	IF	CITATIONS
130	Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients at Different Postgrafting Periods. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 354-361.	1.0	96
131	Pharmacokinetics and Bioavailability of Mycophenolic Acid After Intravenous Administration and Oral Administration of Mycophenolate Mofetil to Heart Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 315-321.	1.0	34
133	Mycophenolate Mofetil in Islet Cell Transplant: Variable Pharmacokinetics but Good Correlation Between Total and Unbound Concentrations. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 901-909.	1.0	14
134	Simultaneous determination of mycophenolic acid and its phenolic glucuronide in human plasma using an isocratic high-performance liquid chromatography procedure. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 817, 327-330.	1.2	28
135	Quantification of total and free mycophenolic acid in human plasma by liquid chromatography with fluorescence detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 817, 207-213.	1.2	35
136	Drug interaction between mycophenolate mofetil and rifampin: Possible induction of uridine diphosphate-glucuronosyltransferase. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 81-88.	2.3	71
137	Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 34-42.	2.3	31
138	Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 317-321.	2.3	61
139	Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 486-500.	2.3	71
140	Simple High-Performance Liquid Chromatographic Assay, with Post-Column Derivatization, for Simultaneous Determination of Mycophenolic Acid and its Glucuronide Metabolite in Human Plasma and Urine. <i>Chromatographia</i> , 2005, 62, 363-371.	0.7	11
141	AN INVESTIGATION OF HUMAN AND RAT LIVER MICROSOMAL MYCOPHENOLIC ACID GLUCURONIDATION: EVIDENCE FOR A PRINCIPAL ROLE OF UGT1A ENZYMES AND SPECIES DIFFERENCES IN UGT1A SPECIFICITY. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1513-1520.	1.7	51
142	Crohn's-like changes in the colon due to mycophenolate?. <i>Colorectal Disease</i> , 2005, 7, 27-34.	0.7	68
143	Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. <i>Clinical Transplantation</i> , 2005, 19, 551-558.	0.8	44
144	Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , 2005, 9, 780-787.	0.5	25
145	Potential value of high-dose mizoribine as rescue therapy for ongoing acute humoral rejection. <i>Transplant International</i> , 2005, 18, 401-407.	0.8	14
146	Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 249-256.	1.1	82
147	Immunosuppressants: Pharmacokinetics, methods of monitoring and role of high performance liquid chromatography/mass spectrometry. <i>Clinical and Applied Immunology Reviews</i> , 2005, 5, 405-430.	0.4	24
148	Population pharmacokinetic modeling for enterohepatic recirculation in Rhesus monkey. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 26, 151-161.	1.9	20

#	ARTICLE	IF	CITATIONS
149	Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance-Associated Protein 2. <i>American Journal of Transplantation</i> , 2005, 5, 987-994.	2.6	278
150	Pharmacokinetic Principles of Immunosuppressive Drugs. <i>American Journal of Transplantation</i> , 2005, 5, 207-217.	2.6	59
151	Influence of Co-Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 2937-2944.	2.6	72
152	Effects of mycophenolate mofetil on key pattern of coronary restenosis: a cascade of in vitro and ex vivo models. <i>BMC Cardiovascular Disorders</i> , 2005, 5, 9.	0.7	8
153	Validation of a high-performance liquid chromatography method for the measurement of mycophenolic acid and its glucuronide metabolites in plasma. <i>Clinical Biochemistry</i> , 2005, 38, 824-829.	0.8	46
155	Drug Therapy in the Heart Transplant Recipient. <i>Circulation</i> , 2005, 111, 230-239.	1.6	87
156	Quantification of Mycophenolic Acid and Glucuronide Metabolite in Human Serum by HPLC-Tandem Mass Spectrometry. <i>Clinical Chemistry</i> , 2005, 51, 872-877.	1.5	54
157	Mycophenolic acid-treated human dendritic cells have a mature migratory phenotype and inhibit allogeneic responses via direct and indirect pathways. <i>International Immunology</i> , 2005, 17, 351-363.	1.8	44
158	Immunosuppressant Drug Monitoring: Is the Laboratory Meeting Clinical Expectations?. <i>Annals of Pharmacotherapy</i> , 2005, 39, 119-127.	0.9	25
159	Immunomodulatory Therapy for Ocular Inflammatory Disease: A Basic Manual and Review of the Literature. <i>Ocular Immunology and Inflammation</i> , 2005, 13, 335-351.	1.0	72
160	Glucuronidation and the Transport of the Glucuronide Metabolites in LLC-PK1 Cells. <i>Molecular Pharmaceutics</i> , 2005, 2, 428-434.	2.3	13
161	Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 487-503.	1.5	20
162	Glucuronidation in therapeutic drug monitoring. <i>Clinica Chimica Acta</i> , 2005, 358, 2-23.	0.5	47
163	Mycophenolic Acid Metabolite Profile in Renal Transplant Patients Receiving Enteric-Coated Mycophenolate Sodium or Mycophenolate Mofetil. <i>Transplantation Proceedings</i> , 2005, 37, 852-855.	0.3	51
164	Pharmacokinetics of Mycophenolic Acid in Kidney Transplant Patients Receiving Sirolimus Versus Cyclosporine. <i>Transplantation Proceedings</i> , 2005, 37, 864-866.	0.3	15
165	Mycophenolate Mofetil Pharmacokinetic Monitoring in Pediatric Kidney Transplant Recipients. <i>Transplantation Proceedings</i> , 2005, 37, 856-858.	0.3	10
166	Therapeutic Mycophenolic Acid Monitoring by Means of Limited Sampling Strategy in Orthotopic Heart Transplant Patients. <i>Transplantation Proceedings</i> , 2005, 37, 2240-2243.	0.3	31
167	Pharmacokinetics of Mycophenolate Mofetil in Kidney Transplant Patients With Renal Insufficiency. <i>Transplantation Proceedings</i> , 2005, 37, 3749-3751.	0.3	29

#	ARTICLE	IF	CITATIONS
168	Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 505-526.	1.5	77
169	A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil. Clinical Pharmacokinetics, 2005, 44, 837-847.	1.6	59
170	Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Recipients. Clinical Pharmacokinetics, 2005, 44, 1083-1096.	1.6	85
171	Enteric-Coated Mycophenolate Sodium. Drugs, 2005, 65, 1037-1050.	4.9	78
172	IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM. Drug Metabolism and Disposition, 2005, 33, 139-146.	1.7	251
173	Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Research and Therapy, 2006, 8, R182.	1.6	115
174	Perioperative Management of Immunosuppression. Surgical Clinics of North America, 2006, 86, 1167-1183.	0.5	14
175	Individualisation of mycophenolate mofetil dose in renal transplant recipients. Expert Opinion on Pharmacotherapy, 2006, 7, 361-376.	0.9	19
176	Evaluation of Urinary Methoxyphenols as Biomarkers of Woodsmoke Exposure. Environmental Science & Technology, 2006, 40, 2163-2170.	4.6	33
178	Clinical pharmacokinetics of voriconazole. International Journal of Antimicrobial Agents, 2006, 27, 274-284.	1.1	129
179	Methods To Evaluate Biliary Excretion of Drugs in Humans: An Updated Review. Molecular Pharmaceutics, 2006, 3, 198-211.	2.3	136
180	An isocratic high performance liquid chromatographic method for quantification of mycophenolic acid and its glucuronide metabolite in human serum using liquid-liquid extraction: Application to human pharmacokinetic studies. Clinica Chimica Acta, 2006, 370, 185-190.	0.5	31
181	Inclusion of MPA and in a rapid multi-drug LC-tandem mass spectrometric method for simultaneous determination of immunosuppressants. Clinica Chimica Acta, 2006, 373, 168-171.	0.5	45
182	A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Clinical Therapeutics, 2006, 28, 893-905.	1.1	18
183	Pharmacokinetics of Oral Mycophenolate Mofetil in Dog: Bioavailability Studies and the Impact of Antibiotic Therapy. Biology of Blood and Marrow Transplantation, 2006, 12, 1352-1354.	2.0	19
184	Clinical Pharmacokinetics of Mycophenolate Mofetil in Japanese Renal Transplant Recipients: a Retrospective Cohort Study in a Single Center. Biological and Pharmaceutical Bulletin, 2006, 29, 2099-2105.	0.6	11
185	Quantification and 24-hour Monitoring of Mycophenolic Acid by High-Performance Liquid Chromatography in Japanese Renal Transplant Recipients. Yakugaku Zasshi, 2006, 126, 1357-1362.	0.0	21
186	Characterization of Intestinal Absorption and Enterohepatic Circulation of Mycophenolic Acid and Its 7-O-Glucuronide in Rats. Drug Metabolism and Pharmacokinetics, 2006, 21, 406-413.	1.1	15

#	ARTICLE	IF	CITATIONS
187	Fully Automated Analytical Method for Mycophenolic Acid Quantification in Human Plasma Using On-line Solid Phase Extraction and High Performance Liquid Chromatography With Diode Array Detection. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 505-511.	1.0	16
188	A Limited Sampling Model for Estimation of Total and Unbound Mycophenolic Acid (MPA) Area Under the Curve (AUC) in Hematopoietic Cell Transplantation (HCT). <i>Therapeutic Drug Monitoring</i> , 2006, 28, 394-401.	1.0	28
189	High-Performance Liquid Chromatography Method for the Determination of Mycophenolic Acid and Its Acyl and Phenol Glucuronide Metabolites in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 116-122.	1.0	46
190	Pharmacokinetics of Mycophenolic Acid and Metabolites in Diabetic Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 95-101.	1.0	29
191	Analysis of Mycophenolic Acid in Saliva Using Liquid Chromatography Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 402-406.	1.0	37
192	Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplant Patients Treated With Mycophenolate Mofetil: Review of the Literature. <i>Transplantation</i> , 2006, 82, 1004-1012.	0.5	65
193	Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients. <i>Transplantation</i> , 2006, 82, 1074-1084.	0.5	187
194	Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients. <i>Transplant International</i> , 2006, 19, 44-53.	0.8	4
195	Absence of an interaction between iron and mycophenolate mofetil absorption. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 492-495.	1.1	13
196	A comparison of the effect of ciclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 477-484.	1.1	48
197	Phosphonic acid-containing analogues of mycophenolic acid as inhibitors of IMPDH. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 3479-3483.	1.0	20
198	Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 509-521.	2.3	73
199	Molecularly imprinted solid-phase extraction for rapid screening of mycophenolic acid in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 844, 142-147.	1.2	31
200	Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. <i>European Journal of Clinical Pharmacology</i> , 2006, 63, 27-37.	0.8	35
201	Mycophenolic Acid 12-h Trough Level Monitoring in Renal Transplantation: Association with Acute Rejection and Toxicity. <i>American Journal of Transplantation</i> , 2006, 6, 121-128.	2.6	132
202	Adenovirus-Mediated Gene Therapy to Restore Expression and Functionality of Multiple UDP-Glucuronosyltransferase 1A Enzymes in Gunn Rat Liver. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 1240-1247.	1.3	5
203	Mycophenolate mofetil and systemic lupus erythematosus. <i>Lupus</i> , 2006, 15, 44-54.	0.8	8
204	Pharmacokinetics of Mycophenolic Acid and Its Glucuronidated Metabolites in Stable Lung Transplant Recipients. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1509-1516.	0.9	21

#	ARTICLE	IF	CITATIONS
205	Characterization of Rat Intestinal Microsomal UDP-Glucuronosyltransferase Activity toward Mycophenolic Acid. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1632-1639.	1.7	14
206	Explaining Variability in Mycophenolic Acid Exposure to Optimize Mycophenolate Mofetil Dosing: A Population Pharmacokinetic Meta-Analysis of Mycophenolic Acid in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 871-880.	3.0	175
207	Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1539-1545.	1.7	91
208	Tandem-Massenspektrometrie in der therapeutischen Arzneimittelspiegel-Bestimmung: Praxis und TÄ¼cken der Anwendung / Tandem mass spectrometry in drug monitoring: experience and pitfalls in application. <i>Das Medizinische Laboratorium</i> , 2006, 30, 428-437.	0.0	0
209	Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. <i>Current Medical Research and Opinion</i> , 2006, 22, 2355-2364.	0.9	39
210	Adsorption of Mycophenolic Acid and Its Phenolic Glucuronide to Glass, Polystyrene, and Polypropylene Containers. <i>Clinical Chemistry</i> , 2006, 52, 904-906.	1.5	3
211	Mycophenolate mofetil: long-term outcomes in solid organ transplantation. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 495-518.	1.3	5
212	Therapeutic Drug Monitoring of Mycophenolic Acid. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 1062-1072.	2.2	74
213	Gender-Related Differences in Mycophenolate Mofetil-Induced Gastrointestinal Toxicity in Rats. <i>Drug Metabolism and Disposition</i> , 2007, 35, 449-454.	1.7	16
214	Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis—A multicenter study. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1351-1360.	0.4	28
215	Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2440-2448.	0.4	82
216	KIDNEY TRANSPLANTATION: CURRENT ISSUES AND FUTURE PROSPECTS. <i>Acta Clinica Belgica</i> , 2007, 62, 208-217.	0.5	4
217	Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2497-2503.	0.4	37
218	Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid After Enteric-Coated Mycophenolate Versus Mycophenolate Mofetil in Patients With Progressive IgA Nephritis. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 850-859.	1.0	22
219	Therapeutic Monitoring of Mycophenolate Mofetil. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 184-191.	2.2	99
220	Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 251-261.	1.5	32
221	Influence of UGT1A7 and UGT1A9 Intronic I399 Genetic Polymorphisms on Mycophenolic Acid Pharmacokinetics in Japanese Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 299-304.	1.0	38
222	Prediction of Unbound Mycophenolic Acid Concentrations in Patients After Hematopoietic Cell Transplantation. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 385-390.	1.0	10

#	ARTICLE	IF	CITATIONS
223	Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 321-330.	0.7	68
224	Monitoring of Inosine Monophosphate Dehydrogenase Activity as a Biomarker for Mycophenolic Acid Effect: Potential Clinical Implications. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 141-149.	1.0	39
225	Pharmacokinetics of Mycophenolate Mofetil in Hematopoietic Stem Cell Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 353-360.	1.0	39
226	Enteric-Coated Mycophenolate Sodium Provides Higher Mycophenolic Acid Predose Levels Compared With Mycophenolate Mofetil: Implications for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 381-384.	1.0	34
227	The Impact of Renal Allograft Function on Exposure and Elimination of Mycophenolic Acid (MPA) and Its Metabolite MPA 7-O-glucuronide. <i>Transplantation</i> , 2007, 84, 362-373.	0.5	52
228	Highly Variable Mycophenolate Mofetil Bioavailability Following Nonmyeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 6-12.	1.0	29
229	Noninfectious Gastrointestinal (GI) Complications of Mycophenolic Acid Therapy: A Consequence of Local GI Toxicity?. <i>Transplantation Proceedings</i> , 2007, 39, 88-93.	0.3	73
230	Therapeutic Drug Monitoring of Mycophenolic Acid in Kidney Transplant Patients: A Abbreviated Sampling Strategy. <i>Transplantation Proceedings</i> , 2007, 39, 596-599.	0.3	14
231	Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. <i>Biochimie</i> , 2007, 89, 393-402.	1.3	44
232	Determination of Mycophenolic Acid (MPA) and Its Acyl and Phenol Glucuronide Metabolites Simultaneously in Human Plasma by a Simplified HPLC Method. <i>Analytical Letters</i> , 2007, 40, 2465-2475.	1.0	10
233	Review: Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. <i>Lupus</i> , 2007, 16, 618-626.	0.8	39
234	Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2007, 46, 13-58.	1.6	481
235	Pharmacokinetics of Mycophenolic Acid and Estimation of Exposure Using Multiple Linear Regression Equations in Chinese Renal Allograft Recipients. <i>Clinical Pharmacokinetics</i> , 2007, 46, 389-401.	1.6	22
236	Prodrug Objectives and Design. , 2007, , 1009-1041.		9
237	The Biochemistry of Drug Metabolism “ An Introduction. <i>Chemistry and Biodiversity</i> , 2007, 4, 2031-2122.	1.0	68
238	Regulation of the UGT1A1 bilirubin-conjugating pathway: Role of a new splicing event at the UGT1A locus. <i>Hepatology</i> , 2007, 45, 128-138.	3.6	90
239	MMF to EC-MPS conversion: What makes the difference?. <i>Liver Transplantation</i> , 2007, 13, 773-774.	1.3	10
240	Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. <i>Liver Transplantation</i> , 2007, 13, 791-796.	1.3	30

#	ARTICLE	IF	CITATIONS
241	Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. <i>Liver Transplantation</i> , 2007, 13, 1570-1575.	1.3	18
242	Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients. <i>Clinical Biochemistry</i> , 2007, 40, 752-764.	0.8	35
243	Simple reversed-phase liquid chromatographic assay for simultaneous quantification of free mycophenolic acid and its glucuronide metabolite in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 846, 313-318.	1.2	14
244	Relationship between MPA free fraction and free MPAG concentrations in heart transplant recipients based on simultaneous HPLC quantification of the target compounds in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 852, 674-678.	1.2	15
245	Sensitive high-performance liquid chromatography-tandem mass spectrometry method for quantitative analysis of mycophenolic acid and its glucuronide metabolites in human plasma and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 858, 159-167.	1.2	30
246	Liquid chromatographic determination of mycophenolic acid and its metabolites in human kidney transplant plasma: Pharmacokinetic application. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 859, 276-281.	1.2	27
247	Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. <i>Clinical Transplantation</i> , 2007, 21, 18-23.	0.8	29
248	Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 541-547.	1.1	22
249	Time-dependent clearance of mycophenolic acid in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 741-752.	1.1	63
250	Mycophenolate mofetil. <i>Dermatologic Therapy</i> , 2007, 20, 229-238.	0.8	92
251	Lack of an Effect of Oral Iron Administration on Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Recipients. <i>Pharmacotherapy</i> , 2007, 27, 1272-1278.	1.2	9
252	Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. <i>Biochemical Pharmacology</i> , 2007, 74, 161-168.	2.0	41
253	Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation. <i>American Journal of Transplantation</i> , 2007, 7, 2496-2503.	2.6	368
254	Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 93-107.	1.5	82
255	Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 279-288.	0.8	64
256	Influence of SLCO1B1, 1B3, 2B1 and ABCG2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 1161-1169.	0.8	135
257	Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1047-1056.	0.8	43
258	Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2008, 88, 104-110.	0.7	24

#	ARTICLE	IF	CITATIONS
259	Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients. <i>Pediatric Nephrology</i> , 2008, 23, 1859-1865.	0.9	23
260	Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: Prediction of occurrence of leukopenia. <i>Liver Transplantation</i> , 2008, 14, 1165-1173.	1.3	26
261	A simple and rapid CZE method for the analysis of mycophenolic acid and its phenol glucuronide metabolite in human serum. <i>Electrophoresis</i> , 2008, 29, 3658-3664.	1.3	12
262	Mycophenolate mofetil embryopathy may be dose and timing dependent. <i>American Journal of Medical Genetics, Part A</i> , 2008, 146A, 1963-1966.	0.7	40
263	Simultaneous determination of mycophenolic acid and its glucuronides in human plasma using isocratic ion pair high-performance liquid chromatography. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 46, 603-608.	1.4	34
264	Simultaneous determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human serum by capillary zone electrophoresis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 47, 201-206.	1.4	16
266	Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2008, 42, 113-120.	1.3	32
267	Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2008, 41, 667-674.	1.3	25
268	Expression of Inosine Monophosphate Dehydrogenase Type I and Type II After Mycophenolate Mofetil Treatment: A 2-year Follow-up in Kidney Transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 328-335.	2.3	24
269	Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis. <i>Nephrology</i> , 2008, 13, 331-336.	0.7	16
270	Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 893-907.	1.1	59
271	No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 33, 193-201.	0.7	31
272	Population Pharmacokinetics of Mycophenolic Acid. <i>Clinical Pharmacokinetics</i> , 2008, 47, 827-838.	1.6	79
273	Enteric-Coated Mycophenolate Sodium. <i>Drugs</i> , 2008, 68, 2505-2533.	4.9	17
274	Performance of Limited Sampling Strategies for Predicting Mycophenolic Acid Area Under the Curve in Thoracic Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 325-328.	0.3	11
275	Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients. <i>International Immunopharmacology</i> , 2008, 8, 769-773.	1.7	17
276	Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology. <i>Clinica Chimica Acta</i> , 2008, 389, 87-92.	0.5	32
277	Current target ranges of mycophenolic acid exposure and drug-related adverse events: A 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. <i>Clinical Therapeutics</i> , 2008, 30, 673-683.	1.1	100

#	ARTICLE	IF	CITATIONS
278	Higher Mycophenolate Dose Requirements in Children Undergoing Hematopoietic Cell Transplant (HCT). <i>Journal of Clinical Pharmacology</i> , 2008, 48, 485-494.	1.0	19
279	Individualizing Therapy in Patients With Chronic Kidney Disease. <i>Journal of Pharmacy Practice</i> , 2008, 21, 225-236.	0.5	0
280	Measurement of mycophenolic acid in plasma or serum by a commercial enzyme inhibition technique in comparison with a high performance liquid chromatography method. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 1281-4.	1.4	3
281	Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 879-886.	0.9	16
282	Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. <i>Pharmacogenomics</i> , 2008, 9, 869-879.	0.6	40
283	Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. <i>Xenobiotica</i> , 2008, 38, 1422-1436.	0.5	49
284	Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3514-3520.	0.4	77
285	Pharmacokinetics of Mycophenolic Acid and its Phenolic-Glucuronide and Acyl Glucuronide Metabolites in Stable Thoracic Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 282-291.	1.0	26
286	Role of Pharmacogenetics of Immunosuppressive Drugs in Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 143-150.	1.0	55
287	Limited Sampling Strategy for Simultaneous Estimation of the Area Under the Concentration-Time Curve of Tacrolimus and Mycophenolic Acid in Adult Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 52-59.	1.0	46
288	Evaluation of MPA and MPAG Removal by Continuous Venovenous Hemodiafiltration and Continuous Venovenous Hemofiltration. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 100-102.	1.0	5
289	Comparison of Pharmacokinetics of Mycophenolic Acid and Its Glucuronide Between Patients With Lupus Nephritis and With Kidney Transplantation. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 656-661.	1.0	25
290	Influence of Drug Transporters and UGT Polymorphisms on Pharmacokinetics of Phenolic glucuronide Metabolite of Mycophenolic Acid in Japanese Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 559-564.	1.0	73
291	Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review. <i>Transplantation</i> , 2008, 85, 1675-1685.	0.5	119
292	AcylMPAG Plasma Concentrations and Mycophenolic Acid-Related Side Effects in Patients Undergoing Renal Transplantation Are Not Related to the UGT2B7-840G>A Gene Polymorphism. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 439-444.	1.0	40
293	Mycophenolate mofetil in the treatment of lupus nephritis. <i>Biologics: Targets and Therapy</i> , 2008, 2, 297.	3.0	9
294	Defining Algorithms for Efficient Therapeutic Drug Monitoring of Mycophenolate Mofetil in Heart Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 419-427.	1.0	26
295	Age-Related Variability of Mycophenolate Mofetil Exposure in Stable Pediatric Liver Transplant Recipients and Influences of Donor Characteristics. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 727-733.	1.0	10

#	ARTICLE	IF	CITATIONS
296	Population Pharmacokinetics of Mycophenolic Acid and Its 2 Glucuronidated Metabolites in Kidney Transplant Recipients. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 185-195.	1.0	24
297	Mechanism-Based Enterohepatic Circulation Model of Mycophenolic Acid and Its Glucuronide Metabolite: Assessment of Impact of Cyclosporine Dose in Asian Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 684-699.	1.0	27
298	Impact of Calcineurin Inhibitors on Urinary Excretion of Mycophenolic Acid and Its Glucuronide in Kidney Transplant Recipients. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 710-718.	1.0	13
299	Population Pharmacokinetics of Acyclovir in Children and Young People with Malignancy after Administration of Intravenous Acyclovir or Oral Valacyclovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2918-2927.	1.4	16
300	Clinical utility of therapeutic drug monitoring of mycophenolic acid in transplantation medicine: Where are we? / Der klinische Nutzen des Therapeutischen Drug Monitoring von Mycophenolsäure in der Transplantationsmedizin: Wo stehen wir?. <i>Laboratoriums Medizin</i> , 2009, 33, 88-98.	0.1	1
301	Influence of Clinical and Demographic Variables on Mycophenolic Acid Pharmacokinetics in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1020-1027.	0.9	16
302	Effect of Mycophenolate Acyl-Glucuronide on Human Recombinant Type 2 Inosine Monophosphate Dehydrogenase. <i>Clinical Chemistry</i> , 2009, 55, 986-993.	1.5	31
303	Pharmacokinetics of Mycophenolic Acid in Patients with Lupus Nephritis. <i>Pharmacotherapy</i> , 2009, 29, 7-16.	1.2	25
304	Long-term Management of the Liver Transplant Patient: Recommendations for the Primary Care Doctor. <i>American Journal of Transplantation</i> , 2009, 9, 1988-2003.	2.6	66
305	Identification and characterization of molecular targets of natural products by mass spectrometry. <i>Mass Spectrometry Reviews</i> , 2010, 29, 126-155.	2.8	57
306	Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. <i>Liver Transplantation</i> , 2009, 15, 136-147.	1.3	36
307	Comparison of pharmacokinetics of mycophenolic acid and its metabolites between living donor liver transplant recipients and deceased donor liver transplant recipients. <i>Liver Transplantation</i> , 2009, 15, 1473-1480.	1.3	6
308	HPLC-UV assay for monitoring total and unbound mycophenolic acid concentrations in children. <i>Biomedical Chromatography</i> , 2009, 23, 92-100.	0.8	22
309	Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 541-564.	0.8	73
310	No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 1047-1053.	0.8	30
311	Two sampling time profiles for the abbreviated estimation of mycophenolic acid area under the curve in adult renal transplant recipients treated with mycophenolate mofetil and concomitant tacrolimus. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2009, 34, 531-537.	0.7	2
312	Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2009, 34, 683-692.	0.7	12
313	Increased Mycophenolic Acid Exposure in Stable Kidney Transplant Recipients on Tacrolimus as Compared With Those on Sirolimus: Implications for Pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 411-415.	2.3	20

#	ARTICLE	IF	CITATIONS
314	UGT Genotype May Contribute to Adverse Events Following Medication With Mycophenolate Mofetil in Pediatric Kidney Transplant Recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 495-500.	2.3	38
315	Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2009, 44, 113-120.	1.3	26
316	Longitudinal evaluation of mycophenolic acid pharmacokinetics in pediatric kidney transplant recipients. The role of post-transplant clinical and therapeutic variables. <i>Clinical Transplantation</i> , 2009, 23, 264-270.	0.8	17
317	Determination of total, free and saliva mycophenolic acid with a LC-MS/MS method: Application to pharmacokinetic study in healthy volunteers and renal transplant patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 50, 515-521.	1.4	44
318	Measurement of mycophenolic acid and its glucuronide using a novel rapid liquid chromatography-electrospray ionization tandem mass spectrometry assay. <i>Clinical Biochemistry</i> , 2009, 42, 83-90.	0.8	33
319	Cyclosporine concentration-dependent increase in concentration ratio of mycophenolic acid acyl and phenol glucuronides to mycophenolic acid in stable kidney transplant recipients. <i>Clinical Biochemistry</i> , 2009, 42, 595-601.	0.8	13
320	Measurement of Total and Unbound Mycophenolic Acid and Its Glucuronide by LC Coupled with MS. Application to a Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Autoimmune Diseases. <i>Chromatographia</i> , 2009, 70, 939-945.	0.7	8
321	Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. <i>Xenobiotica</i> , 2009, 39, 407-414.	0.5	17
322	The Prevalence of Uridine Diphosphate-Glucuronosyltransferase 1A9 (UGT1A9) Gene Promoter Region Single-Nucleotide Polymorphisms T-275A and C-2152T and Its Influence on Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Patients. <i>Transplantation Proceedings</i> , 2009, 41, 2313-2316.	0.3	38
323	Validation of Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure During the First Year After Heart Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 4277-4284.	0.3	11
324	Enteric-Coated Mycophenolate Sodium Reduces Gastrointestinal Symptoms in Renal Transplant Patients. <i>Transplantation Proceedings</i> , 2009, 41, 4159-4164.	0.3	21
325	Mycophenolate mofetil in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 183-199.	0.6	108
326	Proton Pump Inhibitor Co-medication Reduces Mycophenolate Acid Drug Exposure in Heart Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 605-611.	0.3	52
327	Mycophenolic Acid Exposure after Administration of Mycophenolate Mofetil in the Presence and Absence of Cyclosporin in Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 329-341.	1.6	40
328	Pharmacokinetic Modelling of the Plasma Protein Binding of Mycophenolic Acid in Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 463-476.	1.6	35
329	Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part I. <i>Clinical Pharmacokinetics</i> , 2009, 48, 419-462.	1.6	55
330	Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part II. <i>Clinical Pharmacokinetics</i> , 2009, 48, 489-516.	1.6	38
331	Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study. <i>Journal of Translational Medicine</i> , 2009, 7, 64.	1.8	10

#	ARTICLE	IF	CITATIONS
332	Immunotherapy in Elderly Transplant Recipients. <i>Drugs and Aging</i> , 2009, 26, 715-737.	1.3	68
333	A Fast Ultra-Performance Liquid Chromatography Method for Simultaneous Quantification of Mycophenolic Acid and Its Phenol- and Acyl-Glucuronides in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 110-115.	1.0	24
334	Regulation of IL2 and NUCB1 in Mononuclear Cells Treated With Acyl Glucuronide of Mycophenolic Acid Reveals Effects Independent of Inosine Monophosphate Dehydrogenase Inhibition. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 31-41.	1.0	3
335	Limited Sampling Strategies for Therapeutic Drug Monitoring of Mycophenolate Mofetil Therapy in Patients With Autoimmune Disease. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 382-390.	1.0	31
336	Mycophenolic Acid Impedes the Antigen Presenting and Lymph Node Homing Capacities of Human Blood Myeloid Dendritic Cells. <i>Transplantation</i> , 2009, 88, 504-513.	0.5	18
337	Early Phase Limited Sampling Strategy Characterizing Tacrolimus and Mycophenolic Acid Pharmacokinetics Adapted to the Maintenance Phase of Renal Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 467-474.	1.0	27
338	New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 416-435.	1.0	146
339	Mycophenolic Acid 12-Hour Area Under the Curve in De Novo Liver Transplant Patients Given Mycophenolate Mofetil at Fixed Versus Concentration-Controlled Doses. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 451-456.	1.0	7
340	What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?. <i>Current Opinion in Rheumatology</i> , 2009, 21, 256-261.	2.0	12
341	Performance of the New Mycophenolate Assay Based on IMPDH Enzymatic Activity for Pharmacokinetic Investigations and Setup of Bayesian Estimators in Different Populations of Allograft Recipients. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 443-450.	1.0	11
342	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 5074-5082.	0.6	143
343	Limited Sampling Strategies Drawn Within 3 Hours Postdose Poorly Predict Mycophenolic Acid Area-Under-the-Curve After Enteric-Coated Mycophenolate Sodium. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 585-591.	1.0	27
344	An Investigation Into the Bias Between Liquid Chromatography-Tandem Mass Spectrometry and an Enzyme Multiplied Immunoassay Technique for the Measurement of Mycophenolic Acid. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 420-426.	1.0	17
345	Establishment of High-Performance Liquid Chromatography and Enzyme Multiplied Immunoassay Technology Methods for Determination of Free Mycophenolic Acid and Its Application in Chinese Liver Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 653-660.	1.0	31
346	Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 537-543.	0.7	48
347	Population Pharmacokinetics Analysis of Mycophenolic Acid in Adult Kidney Transplant Patients With Chronic Graft Dysfunction. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 427-432.	1.0	15
348	Evaluation of Limited Sampling Strategies for Mycophenolic Acid After Mycophenolate Mofetil Intake in Adult Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 723-733.	1.0	26
349	Developmental Pharmacogenetics of Immunosuppressants in Pediatric Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 688-699.	1.0	32

#	ARTICLE	IF	CITATIONS
350	Differences in Clearance of Mycophenolic Acid Among Renal Transplant Recipients, Hematopoietic Stem Cell Transplant Recipients, and Patients With Autoimmune Disease. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 606-614.	1.0	34
351	Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 production. <i>Kidney International</i> , 2010, 78, 79-88.	2.6	28
353	A Reliable Limited Sampling Strategy for the Estimation of Mycophenolic Acid Area Under the Concentration Time Curve in Adult Renal Transplant Patients in the Stable Posttransplant Period. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 136-140.	1.0	19
355	Enterohepatic Circulation Model for Population Pharmacokinetic Analysis. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 51, 1143-1148.	1.2	47
356	UPLC Analysis of Mycophenolic Acid and Its Phenol and Acyl Glucuronide Metabolites in Human Plasma. <i>Chromatographia</i> , 2010, 72, 747-752.	0.7	4
357	Use of two validated in vitro tests to assess the embryotoxic potential of mycophenolic acid. <i>Archives of Toxicology</i> , 2010, 84, 37-43.	1.9	23
358	Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1119-1130.	0.8	17
359	Personalized immunosuppressive therapy in pediatric heart transplantation: Progress, pitfalls and promises. <i>Journal of Intensive Care Medicine</i> , 2010, 25, 146-158.		20
360	Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, two-way crossover study. <i>Clinical Therapeutics</i> , 2010, 32, 171-178.	1.1	12
361	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. <i>Arthritis and Rheumatism</i> , 2010, 62, 2047-2054.	6.7	85
362	Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 358-366.	1.1	34
363	Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8*2 variant allele. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 675-683.	1.1	40
364	Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 567-579.	1.1	25
365	The Role of Organic Anion-Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 100-108.	2.3	143
366	A clinical assessment of mycophenolate drug monitoring after liver transplantation. <i>Clinical Transplantation</i> , 2010, 24, E35-42.	0.8	19
367	Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 341-358.	2.2	276
368	Involvement of Carboxylesterase 1 and 2 in the Hydrolysis of Mycophenolate Mofetil. <i>Drug Metabolism and Disposition</i> , 2010, 38, 2210-2217.	1.7	64
369	Treatment of Primary Systemic Vasculitis with the Inosine Monophosphate Dehydrogenase Inhibitor Mycophenolic Acid. <i>Nephron Clinical Practice</i> , 2010, 116, c1-c10.	2.3	13

#	ARTICLE	IF	CITATIONS
370	<i>SLCO1B1</i> genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. <i>Pharmacogenomics</i> , 2010, 11, 1703-1713.	0.6	48
371	Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 503-511.	2.2	40
372	Determination of mycophenolic acid and its phenyl glucuronide in human plasma, ultrafiltrate, blood, DBS and dried plasma spots. <i>Bioanalysis</i> , 2010, 2, 1423-1435.	0.6	46
373	Pharmacogenetic influences on mycophenolate therapy. <i>Pharmacogenomics</i> , 2010, 11, 369-390.	0.6	47
374	Multiple Peaking Phenomena in Pharmacokinetic Disposition. <i>Clinical Pharmacokinetics</i> , 2010, 49, 351-377.	1.6	115
375	An Age-Dependent Pharmacokinetic Study of Intravenous and Oral Mycophenolate Mofetil in Combination with Tacrolimus for GVHD Prophylaxis in Pediatric Allogeneic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 333-343.	2.0	52
376	Mycophenolate Pharmacokinetics and Association with Response to Acute Graft-versus-Host Disease Treatment from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 421-429.	2.0	32
377	Sample cleanup-free determination of mycophenolic acid and its glucuronide in serum and plasma using the novel technology of ultra-performance liquid chromatographyâ€“electrospray ionization tandem mass spectrometry. <i>Talanta</i> , 2010, 80, 1894-1898.	2.9	21
378	Pharmacokinetics of Mycophenolic Acid in Living Donor Liver Transplantation. <i>Transplantation Proceedings</i> , 2010, 42, 846-853.	0.3	6
379	Mycophenolic acid attenuates tumor necrosis factor- α -induced endothelin-1 production in human aortic endothelial cells. <i>Atherosclerosis</i> , 2010, 211, 48-54.	0.4	23
380	Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 237-244.	1.5	1
381	The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 731-743.	1.5	34
382	Primary Care of the Liver Transplant Recipient. <i>Primary Care - Clinics in Office Practice</i> , 2011, 38, 499-514.	0.7	4
383	Mycophenolate Mofetil for the Management of Autoimmune Bullous Diseases. <i>Dermatologic Clinics</i> , 2011, 29, 555-559.	1.0	19
384	The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease. <i>Clinical Pharmacokinetics</i> , 2011, 50, 1-24.	1.6	50
385	Systemic Therapy With Conventional and Novel Immunomodulatory Agents for Ocular Inflammatory Disease. <i>Survey of Ophthalmology</i> , 2011, 56, 474-510.	1.7	59
386	Clinical Pharmacokinetics of Triple Immunosuppression Scheme in Kidney Transplant (Tacrolimus,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		2
387	Mycophenolic acid in Rheumatology: mechanisms of action and severe adverse events. <i>Reumatismo</i> , 2011, 62, 91-100.	0.4	6

#	ARTICLE	IF	CITATIONS
388	Pharmacokinetic Drug Interaction of Mycophenolate With Co-Amoxiclav in Renal Transplant Patients. <i>Transplantation</i> , 2011, 91, e36-e38.	0.5	15
389	Therapeutic Drug Monitoring of Mycophenolic Acid After Lung Transplantation—Is It Clinically Relevant?. <i>Transplantation</i> , 2011, 91, e33-e34.	0.5	2
390	Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients. <i>Transplantation</i> , 2011, 92, 321-327.	0.5	11
391	Monitoring Nonadherence and Acute Rejection With Variation in Blood Immunosuppressant Levels in Pediatric Renal Transplantation. <i>Transplantation</i> , 2011, 92, 918-922.	0.5	101
392	The Pharmacokinetics of Enteric-Coated Mycophenolate Sodium and Its Gastrointestinal Side Effects in De Novo Renal Transplant Recipients of Hispanic Ethnicity. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 45-49.	1.0	11
393	Renal Graft Function and Low-Dose Cyclosporine Affect Mycophenolic Acid Pharmacokinetics in Kidney Transplantation. <i>Transplantation</i> , 2011, 92, 550-556.	0.5	7
394	Monitoring of Mycophenolic Acid Predose Concentrations in the Maintenance Phase More Than One Year After Renal Transplantation. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 295-302.	1.0	15
395	Pharmacokinetic Variability of Mycophenolic Acid and Its Glucuronide in Systemic Lupus Erythematosus Patients in Remission Maintenance Phase. <i>Biological and Pharmaceutical Bulletin</i> , 2011, 34, 755-759.	0.6	12
396	Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin. <i>Clinical Transplantation</i> , 2011, 25, 222-227.	0.8	14
397	Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 217-224.	0.7	6
398	Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report. <i>Transplantation Reviews</i> , 2011, 25, 65-77.	1.2	23
399	Mycophenolic acid in kidney transplant patients with diabetes mellitus: does the formulation matter?. <i>Transplantation Reviews</i> , 2011, 25, 117-123.	1.2	7
400	Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. <i>Transplantation Reviews</i> , 2011, 25, 78-89.	1.2	66
401	Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients. <i>Transplant International</i> , 2011, 24, 276-283.	0.8	11
402	Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. <i>Liver Transplantation</i> , 2011, 17, 1152-1158.	1.3	18
403	Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients—results of the Pharmacogenomic Substudy within the Symphony Study. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3784-3793.	0.4	37
404	Mycophenolic Acid Pharmacokinetics During Maintenance Immunosuppression in African American and Caucasian Renal Transplant Recipients. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1213-1222.	1.0	24
405	Human Pharmacokinetic Prediction of UDP-Glucuronosyltransferase Substrates with an Animal Scale-Up Approach. <i>Drug Metabolism and Disposition</i> , 2011, 39, 820-829.	1.7	42

#	ARTICLE	IF	CITATIONS
406	Performance of the Roche Total Mycophenolic Acid [®] assay on the Cobas Integra 400 [®] , Cobas 6000 [®] and comparison to LC-MS/MS in liver transplant patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1159-65.	1.4	15
407	Differential Kidney Proteome Profiling in a Murine Model of Renal Fibrosis under Treatment with Mycophenolate Mofetil. <i>Pathobiology</i> , 2011, 78, 162-170.	1.9	12
408	Mycophenolate mofetil for the induction and maintenance treatment of lupus nephritis. <i>Immunotherapy</i> , 2011, 3, 1431-1440.	1.0	1
409	Mycophenolic Acid Differentially Impacts B Cell Function Depending on the Stage of Differentiation. <i>Journal of Immunology</i> , 2011, 187, 3603-3612.	0.4	70
410	Evaluation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3019-3025.	0.4	25
411	UGT1A9, UGT2B7, and MRP2 Genotypes Can Predict Mycophenolic Acid Pharmacokinetic Variability in Pediatric Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 671-679.	1.0	48
413	Human β -Hydrolase Domain Containing 10 (ABHD10) Is Responsible Enzyme for Deglucuronidation of Mycophenolic Acid Acyl-glucuronide in Liver. <i>Journal of Biological Chemistry</i> , 2012, 287, 9240-9249.	1.6	31
414	Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 134-142.	0.5	9
415	The Emerging Role of Human Esterases. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 466-477.	1.1	175
416	Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 515-524.	1.1	25
417	Immunosuppression. , 2012, , 371-381.		0
418	Population Pharmacokinetics of Unbound Mycophenolic Acid in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1665-1675.	1.0	22
419	Impact of Glomerular Kidney Diseases on the Clearance of Drugs. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 23S-34S.	1.0	12
420	Important Drug Interactions in Hematopoietic Stem Cell Transplantation: What Every Physician Should Know. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 989-1006.	2.0	78
421	The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals. <i>Clinica Chimica Acta</i> , 2012, 413, 683-690.	0.5	42
424	Bayesian Estimation of Mycophenolate Mofetil in Lung Transplantation, Using a Population Pharmacokinetic Model Developed in Kidney and Lung Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2012, 51, 29-39.	1.6	28
426	Overview of Immunosuppressive Therapies in Renal Transplantation. , 2012, , 97-127.		5
427	Mycophenolate Mofetil for the Management of Autoimmune Bullous Diseases. <i>Immunology and Allergy Clinics of North America</i> , 2012, 32, 309-315.	0.7	9

#	ARTICLE	IF	CITATIONS
428	Drug choices in autoimmune hepatitis: Part B – nonsteroids. Expert Review of Gastroenterology and Hepatology, 2012, 6, 617-635.	1.4	38
429	Immunosuppressive Therapy After Cardiac Transplantation. , 2012, , .		2
430	Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis. International Journal of Hematology, 2012, 96, 10-25.	0.7	28
431	Liquid chromatography–tandem mass spectrometry method for the quantification of mycophenolic acid and its phenolic glucuronide in saliva and plasma using a standardized saliva collection device. Journal of Chromatography A, 2012, 1241, 52-59.	1.8	35
432	Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 217-220.	0.7	11
433	Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. British Journal of Clinical Pharmacology, 2012, 73, 727-740.	1.1	42
434	Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers. European Journal of Clinical Pharmacology, 2013, 69, 843-849.	0.8	31
435	Mathematical Equations to Calculate True Mycophenolic Acid Concentration in Human Plasma by Using Two Immunoassays With Different Cross-Reactivities With Acyl Glucuronide Metabolite: Comparison of Calculated Values With Values Obtained by Using an HPLC–UV Method. Journal of Clinical Laboratory Analysis. 2013. 27. 290-293.	0.9	3
436	Consequences of Gastrointestinal Surgery on Drug Absorption. Nutrition in Clinical Practice, 2013, 28, 429-436.	1.1	30
437	Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4. Translational Research, 2013, 162, 398-409.	2.2	61
438	The pharmacokinetic interaction between mycophenolic acid and cyclosporine revisited: a commentary on –Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus– Xenobiotica, 2013, 43, 836-838.	0.5	10
439	Effects of mycophenolic acid alone and in combination with its metabolite mycophenolic acid glucuronide on rat embryos in vitro. Archives of Toxicology, 2013, 87, 361-370.	1.9	9
440	Positive Bias in Mycophenolic Acid Concentrations Determined by the CEDIA Assay Compared to HPLC–UV Method: Is CEDIA Assay Suitable for Therapeutic Drug Monitoring of Mycophenolic Acid?. Journal of Clinical Laboratory Analysis, 2013, 27, 77-80.	0.9	7
441	Genetic polymorphisms of UGT1A8, UGT1A9 and HNF-1 β and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Transplant Immunology, 2013, 29, 155-161.	0.6	5
442	Comparison of mycophenolic acid concentrations determined by a new PETINIA assay on the Dimension EXL analyzer and a HPLC-UV method. Clinical Biochemistry, 2013, 46, 685-687.	0.8	18
443	Enhanced Poison Elimination in Critical Care. Advances in Chronic Kidney Disease, 2013, 20, 94-101.	0.6	18
444	Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. British Journal of Clinical Pharmacology, 2013, 75, 463-475.	1.1	26
445	Synthesis and Characterization of an Anti-Apoptotic Immunosuppressive Compound for Improving the Outcome of Islet Transplantation. Bioconjugate Chemistry, 2013, 24, 2036-2044.	1.8	7

#	ARTICLE	IF	CITATIONS
446	Circadian variation in haematological toxicity of the immunosuppressive agent "Mycophenolate Mofetil" in rats. <i>Journal of Applied Biomedicine</i> , 2013, 11, 71-78.	0.6	11
447	A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trial. <i>BMJ Open</i> , 2013, 3, e003511.	0.8	2
449	Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2013, 73, 117-124.	0.6	13
450	Evaluation of Mycophenolic Acid Exposure Using a Limited Sampling Strategy in Renal Transplant Recipients. <i>American Journal of Nephrology</i> , 2013, 37, 534-540.	1.4	12
451	New perspectives and insights to Asian systemic lupus erythematosus: renal disease, genetic predisposition and disease activity. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 611-614.	0.9	3
452	IN VITRO EVIDENCE FOR MYCOPHENOLIC ACID DOSE-RELATED CYTOTOXICITY IN HUMAN RETINAL CELLS. <i>Retina</i> , 2013, 33, 2155-2161.	1.0	9
453	Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. <i>Annals of Transplantation</i> , 2013, 18, 43-52.	0.5	7
454	Transplant Coordinators' Perceived Impact of Availability of Multiple Generic Immunosuppression Therapies on Patients, Workload, and Posttransplant Maintenance Therapy. <i>Journal of Transplantation</i> , 2013, 2013, 1-7.	0.3	4
455	Clinical Pharmacology and Therapeutic Drug Monitoring of Immunosuppressive Agents. , 2013, , .		1
457	In vitro activity of immunosuppressive drugs against <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2014, 13, 476.	0.8	11
458	Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. <i>Kidney International</i> , 2014, 85, 1434-1443.	2.6	38
459	Systemic Treatment of Hand Eczema: Mycophenolate Mofetil. , 2014, , 389-395.		0
460	Overdose of mycophenolate mofetil managed in a secondary care hospital in South India. <i>Indian Journal of Pharmacology</i> , 2014, 46, 337.	0.4	3
461	The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1368-1374.	1.0	27
462	Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?. <i>Transplant International</i> , 2014, 27, 994-1004.	0.8	34
463	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 73-79.	0.7	61
464	Effects of Unbound Mycophenolic Acid on Inosine Monophosphate Dehydrogenase Inhibition in Pediatric Kidney Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 716-723.	1.0	14
465	Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 256-262.	0.7	27

#	ARTICLE	IF	CITATIONS
466	Limited Sampling Model for Advanced Mycophenolic Acid Therapeutic Drug Monitoring After Liver Transplantation. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 141-147.	1.0	19
467	Tacrolimus Exposure and Mycophenolate Pharmacokinetics and Pharmacodynamics Early After Liver Transplantation. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 46-53.	1.0	7
468	Effect of Cyclosporine on Steady-State Pharmacokinetics of MPA in Renal Transplant Recipients Is Not Affected by the MPA Formulation. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 456-464.	1.0	11
469	Determination of mycophenolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry. <i>Journal of Pharmaceutical Analysis</i> , 2014, 4, 205-216.	2.4	14
470	Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development. <i>Drug Metabolism and Disposition</i> , 2014, 42, 650-664.	1.7	53
471	Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 92-116.		151
472	Development of tamoxifen-phospholipid complex: Novel approach for improving solubility and bioavailability. <i>International Journal of Pharmaceutics</i> , 2014, 473, 1-9.	2.6	92
473	A Prospective Analysis of the Effects of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil Co-medicated With a Proton Pump Inhibitor in Kidney Transplant Recipients at a Single Institute in China. <i>Transplantation Proceedings</i> , 2014, 46, 1362-1365.	0.3	18
474	Drug Interactions and Antiretroviral Drug Monitoring. <i>Current HIV/AIDS Reports</i> , 2014, 11, 212-222.	1.1	38
475	Mathematical Modeling of the <i>in Vitro</i> Hepatic Disposition of Mycophenolic Acid and Its Glucuronide in Sandwich-Cultured Human Hepatocytes. <i>Molecular Pharmaceutics</i> , 2014, 11, 568-579.	2.3	25
476	Short-term therapeutic drug monitoring of mycophenolic acid reduces infection: a prospective, single-center cohort study in Chinese living-related kidney transplantation. <i>Transplant Infectious Disease</i> , 2014, 16, 760-766.	0.7	6
477	Acute mycophenolate overdose: case series and systematic literature analysis. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 525-534.	1.0	10
478	Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated with Mycophenolate Mofetil. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1121-1129.	2.0	21
479	Mycophenolic acid mediated disruption of the intestinal epithelial tight junctions. <i>Experimental Cell Research</i> , 2014, 322, 277-289.	1.2	40
480	Concomitant Proton Pump Inhibitors With Mycophenolate Mofetil and the Risk of Rejection in Kidney Transplant Recipients. <i>Transplantation</i> , 2014, 97, 518-524.	0.5	24
482	Effect of mycophenolic acid on proliferation of dermal papilla cells and induction of anagen hair follicles. <i>Clinical and Experimental Dermatology</i> , 2015, 40, 894-902.	0.6	15
483	Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1064-1075.	1.1	12
484	Liquid chromatography tandem mass spectrometry method for the quantitation of mycophenolate mofetil in human plasma: Application to a bioequivalence study and metabolite identification. <i>Journal of Separation Science</i> , 2015, 38, 3533-3544.	1.3	5

#	ARTICLE	IF	CITATIONS
485	Limited Sampling Strategy for Predicting Area Under the Concentration–Time Curve for Mycophenolic Acid in Chinese Adults Receiving Mycophenolate Mofetil and Tacrolimus Early After Renal Transplantation. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 304-310.	1.0	11
486	Sensitive and validated LC–MS/MS methods to evaluate mycophenolic acid pharmacokinetics and pharmacodynamics in hematopoietic stem cell transplant patients. <i>Biomedical Chromatography</i> , 2015, 29, 1309-1316.	0.8	27
487	Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 516-523.	1.0	7
488	Population pharmacokinetics of mycophenolic acid in lung transplant recipients with and without cystic fibrosis. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 673-679.	0.8	7
489	Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 95-106.	0.8	22
490	Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: Use of a carboxylate prodrug to improve bioavailability. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 779-790.	1.4	13
492	Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. <i>Pharmacogenomics</i> , 2015, 16, 649-665.	0.6	19
493	Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 921-936.	1.5	28
494	Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 644-650.	2.8	24
495	Update on the Teratogenicity of Maternal Mycophenolate Mofetil. <i>Journal of Pediatric Genetics</i> , 2015, 04, 042-055.	0.3	71
496	The Impact and Treatment of Obesity in Kidney Transplant Candidates and Recipients. <i>Canadian Journal of Kidney Health and Disease</i> , 2015, 2, 59.	0.6	26
497	Gastrointestinal toxicity of mycophenolate mofetil in rats: Effect of administration time. <i>Chronobiology International</i> , 2015, 32, 1373-1384.	0.9	3
498	Formulation, optimization and in vitro–in vivo evaluation of febuxostat nanosuspension. <i>International Journal of Pharmaceutics</i> , 2015, 478, 540-552.	2.6	103
499	Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. <i>Toxicology Letters</i> , 2015, 232, 193-202.	0.4	22
500	In vitro glucuronidation of the primary metabolite of 10-chloromethyl-11-demethyl-12-oxo-calanolide A by human liver microsomes and its interactions with UDP-glucuronosyltransferase substrates. <i>Drug Metabolism and Pharmacokinetics</i> , 2015, 30, 89-96.	1.1	2
501	Pediatric Cardiac Intensive Care Society 2014 Consensus Statement. <i>Pediatric Critical Care Medicine</i> , 2016, 17, S69-S76.	0.2	5
502	A comprehensive review of the published assays for the quantitation of the immunosuppressant drug mycophenolic acid and its glucuronidated metabolites in biological fluids. <i>Biomedical Chromatography</i> , 2016, 30, 721-748.	0.8	15
503	Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients. <i>Pediatric Transplantation</i> , 2016, 20, 492-499.	0.5	14

#	ARTICLE	IF	CITATIONS
504	Drug Use, Dosing, and Toxicity in Renal Disease. , 2016, , 1927-1947.		0
505	Transplant drugs affect the expression of phase II and antioxidant enzymes in human carcinoma cells HepG2 but not in primary cultures of human hepatocytes: In vitro comparative study. Pharmacological Reports, 2016, 68, 1008-1014.	1.5	3
506	Common Drug Interactions Encountered in Treating Transplant-Related Infection. , 2016, , 47-58.		0
507	A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host and Microbe, 2016, 20, 259-270.	5.1	420
508	Circadian variation of cytotoxicity and genotoxicity induced by an immunosuppressive agent α -Mycophenolate Mofetil in rats. Chronobiology International, 2016, 33, 1208-1221.	0.9	4
509	Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. Clinical Pharmacokinetics, 2016, 55, 551-593.	1.6	32
510	Role of enterohepatic recirculation in drug disposition: cooperation and complications. Drug Metabolism Reviews, 2016, 48, 281-327.	1.5	45
511	How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach. Drug Metabolism and Disposition, 2016, 44, 1090-1098.	1.7	35
512	Current methods of the analysis of immunosuppressive agents in clinical materials: A review. Journal of Pharmaceutical and Biomedical Analysis, 2016, 127, 207-231.	1.4	66
513	Developmental changes of MPA exposure in children. Pediatric Nephrology, 2016, 31, 975-982.	0.9	12
514	Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica, 2016, 101, 91-100.	1.7	64
515	Implications of Clinical Mycophenolate Mofetil Dose According to Individual Body Weight in Japanese Renal Transplant Recipients. Transplantation Proceedings, 2016, 48, 35-41.	0.3	3
516	Effect of long-term coadministration of compound glycyrrhizin tablets on the pharmacokinetics of mycophenolic acid in rats. Xenobiotica, 2016, 46, 627-633.	0.5	8
517	Overview of the pharmacology and toxicology of immunosuppressant agents that require therapeutic drug monitoring. , 2016, , 1-27.		2
518	Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine. Clinical and Experimental Nephrology, 2017, 21, 152-158.	0.7	6
519	Comparative metabolism of mycophenolic acid by glucuronic acid and glucose conjugation in human, dog, and cat liver microsomes. Journal of Veterinary Pharmacology and Therapeutics, 2017, 40, 123-129.	0.6	22
520	A novel freeze-dried storage and preparation method for the determination of mycophenolic acid in plasma by high-performance liquid chromatography. Biomedical Chromatography, 2017, 31, e3958.	0.8	3
521	Simultaneous determination of mycophenolic acid and its glucuronide and glycoside derivatives in canine and feline plasma by UHPLC-UV. Biomedical Chromatography, 2017, 31, e3942.	0.8	4

#	ARTICLE	IF	CITATIONS
522	The Roche Total Mycophenolic Acid [®] assay: An application protocol for the ABX Pentra 400 analyzer and comparison with LC [–] MS in children with idiopathic nephrotic syndrome. <i>Practical Laboratory Medicine</i> , 2017, 7, 19-26.	0.6	3
523	Recent Progress in Hepatocyte Culture Models and Their Application to the Assessment of Drug Metabolism, Transport, and Toxicity in Drug Discovery: The Value of Tissue Engineering for the Successful Development of a Microphysiological System. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2302-2311.	1.6	36
524	Association of <i>UGT2B7</i> , <i>UGT1A9</i> , <i>ABCG2</i> , and <i>IL23R</i> polymorphisms with rejection risk in kidney transplant patients. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2017, 80, 661-671.	1.1	9
525	Life-threatening drug interactions: what the physician needs to know. <i>Internal Medicine Journal</i> , 2017, 47, 501-512.	0.5	36
526	Comparison of Mizoribine and Mycophenolate Mofetil With a Tacrolimus-Based Immunosuppressive Regimen in Living-Donor Kidney Transplantation Recipients: A Retrospective Study in China. <i>Transplantation Proceedings</i> , 2017, 49, 26-31.	0.3	11
527	Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 305-307.	1.0	5
528	Meta-analysis reveals a lack of association between MRP2 C-24T genetic polymorphism and the pharmacokinetics of mycophenolic acid in adult renal transplant recipients. <i>Meta Gene</i> , 2017, 11, 91-97.	0.3	1
529	Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection. <i>Biochemical and Biophysical Research Communications</i> , 2017, 494, 298-304.	1.0	15
530	Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 1566-1579.	2.8	26
531	Pharmacokinetics of Mycophenolic Acid after Intravenous Administration of Mycophenolate Mofetil to Healthy Cats. <i>Journal of Veterinary Internal Medicine</i> , 2017, 31, 1827-1832.	0.6	10
532	LC [–] MS/MS method for quantitation of mycophenolic acid, mycophenolic acid acyl-glucuronide, and 7-O-mycophenolic acid glucuronide in serum. <i>Clinical Mass Spectrometry</i> , 2017, 3, 41-48.	1.9	4
533	Modeling Enterohepatic Circulation. <i>Current Pharmacology Reports</i> , 2017, 3, 301-313.	1.5	18
534	Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 29-36.	1.0	16
535	Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2017, 40, e1-e10.	0.6	9
536	In-vitro evaluation of MPA-loaded electrospun coaxial fiber membranes for local treatment of glioblastoma tumor cells. <i>Journal of Drug Delivery Science and Technology</i> , 2017, 40, 45-50.	1.4	27
537	Usefulness of limited sampling strategy for mycophenolic acid area under the curve considering postoperative days in living-donor renal transplant recipients with concomitant prolonged-release tacrolimus. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2017, 3, 17.	0.4	3
538	Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis. <i>Xenobiotica</i> , 2017, 47, 697-704.	0.5	14
539	Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 183-189.	0.6	22

#	ARTICLE	IF	CITATIONS
540	Drug Metabolism in the Liver. <i>Clinics in Liver Disease</i> , 2017, 21, 1-20.	1.0	413
541	Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. <i>Cellular and Molecular Immunology</i> , 2017, 14, 146-179.	4.8	99
542	Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2017, 105, 497-505.	0.7	4
543	Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation. <i>Xenobiotica</i> , 2017, 47, 916-922.	0.5	12
544	Immunosuppressive Drugs. , 2017, , 983-998.e4.		5
545	Pharmacokinetics and Genomics of Immunosuppressive Drugs. , 2017, , 429-443.		1
546	Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 839-846.	1.1	1
547	Determination of Mycophenolic Acid and Mycophenolic Acid Glucuronide Using Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS). <i>Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al]</i> , 2018, 75, 18.21.1-18.21.8.	1.1	3
548	Immunosuppression. , 2018, , 431-444.		0
549	Sandwich-Cultured Hepatocytes for Mechanistic Understanding of Hepatic Disposition of Parent Drugs and Metabolites by Transporter-Enzyme Interplay. <i>Drug Metabolism and Disposition</i> , 2018, 46, 680-691.	1.7	17
550	Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 628-639.	1.0	24
551	Utilization of Biologic and Systemic Agents in the Elderly. , 2018, , 281-294.		0
552	Validation of the cell line LS180 as a model for study of the gastrointestinal toxicity of mycophenolic acid. <i>Xenobiotica</i> , 2018, 48, 433-441.	0.5	3
553	Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. <i>Clinical Pharmacokinetics</i> , 2018, 57, 877-893.	1.6	20
554	Monitoring of Mycophenolic Acid Trough Concentration in Kidney Transplant under Cyclosporine Is Beneficial in Reducing Acute Rejection within 1 Year. <i>The Journal of the Korean Society for Transplantation</i> , 2018, 32, 75.	0.2	0
555	Pharmacokinetic Drug-Drug Interactions Between Immunosuppressant and Anti-Infective Agents: Antimetabolites and Corticosteroids. <i>Annals of Transplantation</i> , 2018, 23, 66-74.	0.5	11
556	Development of a Formula to Correct Particle-Enhanced Turbidimetric Inhibition Immunoassay Values so That it More Precisely Reflects High-Performance Liquid Chromatography Values for Mycophenolic Acid. <i>Transplantation Direct</i> , 2018, 4, e337.	0.8	1
557	Pharmacokinetics and pharmacodynamics of mycophenolic acid in healthy cats after twice-daily intravenous infusion of mycophenolate mofetil for three days. <i>American Journal of Veterinary Research</i> , 2018, 79, 1093-1099.	0.3	3

#	ARTICLE	IF	CITATIONS
558	Impact of UGT2B7 and ABCC2 genetic polymorphisms on mycophenolic acid metabolism in Chinese renal transplant recipients. <i>Pharmacogenomics</i> , 2018, 19, 1323-1334.	0.6	12
559	Pharmacokinetics of Mycophenolate Mofetil and Development of Limited Sampling Strategy in Early Kidney Transplant Recipients. <i>Frontiers in Pharmacology</i> , 2018, 9, 908.	1.6	11
560	Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. <i>Transplantation Proceedings</i> , 2018, 50, 1298-1304.	0.3	7
561	Comparison of pharmacokinetic parameters of mycophenolic acid in two groups of Iranian kidney transplant patients. <i>International Journal of Pharmacokinetics</i> , 2018, 3, 61-68.	0.5	0
562	Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 572-580.	1.0	4
563	Drugs Used in Rheumatic Disease. <i>Handbook of Systemic Autoimmune Diseases</i> , 2018, 15, 39-76.	0.1	2
564	Drug Interactions of Non-HIV Antiviral Agents. , 2018, , 381-424.		0
565	Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor. <i>Clinical Drug Investigation</i> , 2018, 38, 703-713.	1.1	7
566	Enhancement of in vitro dissolution and in vivo performance/oral absorption of FEB-poloxamer-TPGS solid dispersion. <i>Journal of Drug Delivery Science and Technology</i> , 2018, 46, 408-415.	1.4	4
567	Effects of medicines used to treat gastrointestinal diseases on the pharmacokinetics of coadministered drugs: a PEARL Review. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 643-673.	1.2	11
568	Determination of mycophenolic acid in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its pharmacokinetic application in kidney transplant patients. <i>Biomedical Chromatography</i> , 2019, 33, e4681.	0.8	3
569	Pharmacokinetics of mycophenolic acid and its effect on CD4 + and CD8 + T cells after oral administration of mycophenolate mofetil to healthy cats. <i>Journal of Veterinary Internal Medicine</i> , 2019, 33, 2020-2028.	0.6	5
570	Limited Sampling Strategy for the Estimation of Mycophenolic Acid and its Acyl Glucuronide Metabolite Area under the Concentration-Time Curve in Japanese Lung Transplant Recipients. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2019, 22, 407-417.	0.9	6
571	Body mass index, weight-adjusted immunosuppression and the risk of acute rejection and infection after kidney transplantation: a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 2132-2143.	0.4	12
572	Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 1047-1055.	1.0	3
573	Pharmacokinetic Drug-Drug Interactions Between Letemovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1331-1339.	1.0	47
574	Autoimmune rheumatic disease IgG has differential effects upon neutrophil integrin activation that is modulated by the endothelium. <i>Scientific Reports</i> , 2019, 9, 1283.	1.6	13
575	Azathioprine and Mycophenolates. , 2019, , 212-230.		1

#	ARTICLE	IF	CITATIONS
576	Therapeutic Drug Monitoring of Micophenolate Mofetil in Cardiac Transplant Patients by Limited Sampling Strategy: An Update. , 2019, , .		3
577	Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus. British Journal of Clinical Pharmacology, 2019, 85, 746-761.	1.1	23
578	Immunosuppressive drugs and the gastrointestinal tract in renal transplant patients. Transplantation Reviews, 2019, 33, 55-63.	1.2	18
579	Mycophenolic acid in patients with immune-mediated inflammatory diseases: From humans to dogs. Journal of Veterinary Pharmacology and Therapeutics, 2019, 42, 127-138.	0.6	13
580	Impact of SLCO1B3 polymorphisms on clinical outcomes in lung allograft recipients receiving mycophenolic acid. Pharmacogenomics Journal, 2020, 20, 69-79.	0.9	14
581	The pharmacokinetics of mycophenolic acid in rats with orotic acid induced nonalcoholic fatty liver disease. Canadian Journal of Physiology and Pharmacology, 2020, 98, 169-176.	0.7	2
582	Dysregulated FcÎ³ receptor 1a-induced cytokine production in dendritic cells of lupus nephritis patients. Clinical and Experimental Immunology, 2020, 199, 39-49.	1.1	10
583	Mycophenolic Acid and Its Pharmacokinetic Drug-Drug Interactions in Humans: Review of the Evidence and Clinical Implications. Journal of Clinical Pharmacology, 2020, 60, 295-311.	1.0	19
584	Mycophenolates: The latest modern and potent immunosuppressive drugs in adult kidney transplantation: What we should know about them?. Artificial Organs, 2020, 44, 561-576.	1.0	10
585	The effect of mycophenolate mofetil on platelet function. Blood Coagulation and Fibrinolysis, 2020, 31, 132-139.	0.5	3
586	Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study. Drugs in R and D, 2020, 20, 331-342.	1.1	5
587	Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment. , 2020, 215, 107627.		102
588	Successful treatment and long-term follow up of idiopathic immune-mediated polyarthritis with mycophenolate mofetil in a cat. Journal of Feline Medicine and Surgery Open Reports, 2020, 6, 205511692096399.	0.1	0
589	Application of the Extended Clearance Classification System (ECCS) in Drug Discovery and Development: Selection of Appropriate In Vitro Tools and Clearance Prediction. Drug Metabolism and Disposition, 2020, 48, 849-860.	1.7	20
590	Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 769-782.	1.5	19
591	Medical care of liver transplant patients. Expert Review of Gastroenterology and Hepatology, 2020, 14, 901-918.	1.4	3
593	A new model to determine Optimal Exposure to Tacrolimus and Mycophenolate Mofetil after renal transplantation. Clinical Transplantation, 2020, 34, e13893.	0.8	4
595	A Limited Sampling Strategy for Therapeutic Drug Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation. Cell Transplantation, 2020, 29, 096368972091292.	1.2	2

#	ARTICLE	IF	CITATIONS
596	Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. <i>Lupus</i> , 2020, 29, 1067-1077.	0.8	8
597	Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. <i>Cell</i> , 2020, 181, 1661-1679.e22.	13.5	239
598	Effect of the proton-pump inhibitor pantoprazole on Mycophenolic Acid exposure in kidney and liver transplant recipients (IMPACT study): a randomized trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1060-1070.	0.4	8
599	Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. <i>Nature Reviews Neurology</i> , 2020, 16, 154-170.	4.9	65
600	Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. <i>Nature Reviews Rheumatology</i> , 2020, 16, 167-178.	3.5	130
601	Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. <i>Frontiers in Pharmacology</i> , 2020, 11, 340.	1.6	11
602	The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug-Drug Interactions. <i>Pharmaceutics</i> , 2020, 12, 312.	2.0	10
603	Mycophenolates. , 2021, , 178-186.e4.		0
604	Validated LC-MS/MS method for quantitation of total and free mycophenolic acid concentration and its application to a pharmacokinetic study in pediatric renal transplant recipients. <i>Biomedical Chromatography</i> , 2021, 35, e4989.	0.8	5
605	Population pharmacokinetics of mycophenolic acid in paediatric patients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1730-1757.	1.1	15
606	Quantification of mycophenolic acid in human plasma by liquid chromatography with time-of-flight mass spectrometry for therapeutic drug monitoring. <i>Biomedical Chromatography</i> , 2021, 35, e5011.	0.8	2
607	Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 201-213.	1.5	14
608	MRP4 is responsible for the efflux transport of mycophenolic acid β -glucuronide (MPAG) from hepatocytes to blood. <i>Xenobiotica</i> , 2021, 51, 105-114.	0.5	5
609	Management of dyslipidemia in pediatric renal transplant recipients. <i>Pediatric Nephrology</i> , 2021, 36, 51-63.	0.9	9
610	Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. <i>Drugs in Context</i> , 2021, 10, 1-17.	1.0	8
611	Premature senescence of placental decidua cells as a possible cause of miscarriage produced by mycophenolic acid. <i>Journal of Biomedical Science</i> , 2021, 28, 3.	2.6	9
612	Gut microbiota profiles and fecal β -glucuronidase activity in kidney transplant recipients with and without post-transplant diarrhea. <i>Clinical Transplantation</i> , 2021, 35, e14260.	0.8	18
613	Investigating a Modified Apparatus to Discriminate the Dissolution Capacity In Vitro and Establish an IVVC of Mycophenolate Mofetil Tablets in the Fed State. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1240-1247.	1.6	4

#	ARTICLE	IF	CITATIONS
614	Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure in Adult Chinese Heart Transplant Recipients. <i>Frontiers in Pharmacology</i> , 2021, 12, 652333.	1.6	6
615	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 150-200.	1.0	89
616	Immunotherapy for Peripheral Nerve Disorders. <i>Clinics in Geriatric Medicine</i> , 2021, 37, 347-359.	1.0	0
617	Pharmacokinetics of mycophenolate mofetil following single-dose intravenous and single- and multiple-dose oral administration and clinicopathologic effects of mycophenolate mofetil following long-term oral administration in healthy horses. <i>American Journal of Veterinary Research</i> , 2021, 82, 502-509.	0.3	4
618	Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 747-765.	1.5	1
619	Influence of SLCO1B1 521T>C, UGT2B7 802C>T and IMPDH1 $\hat{\sim}$ 106G>A Genetic Polymorphisms on Mycophenolic Acid Levels and Adverse Reactions in Chinese Autoimmune Disease Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 713-722.	0.4	4
620	Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 54-55, 101756.	1.0	12
621	The Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid: Systematic Review and Meta-analysis. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1291-1302.	1.6	12
622	Induction and maintenance immunosuppression in pediatric kidney transplantation – Advances and controversies. <i>Pediatric Transplantation</i> , 2021, 25, e14077.	0.5	10
623	Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 162, 105812.	1.9	137
624	How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not. <i>Kidney International</i> , 2021, 100, 1185-1189.	2.6	17
625	Acute Mycophenolate Mofetil Overdose Managed Conservatively. <i>Cureus</i> , 2021, 13, e17417.	0.2	0
626	Impact of risk-stratified mycophenolate dosing in heart transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14445.	0.8	3
627	Pharmacokinetics of Mycophenolate Mofetil Metabolites in Older Patients on the Seventh Day After Renal Transplantation. <i>Transplantation Proceedings</i> , 2021, 53, 2212-2215.	0.3	2
628	Effects of Corticosteroid Treatment on Mycophenolic Acid Exposure in Renal Transplant Patients – Results From the SAILOR Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 742444.	1.6	2
629	Post-transplant Medication Challenges. , 2021, , 305-356.		0
631	Immunosuppressive Drugs. , 2008, , 165-199.		4
632	Principles of drug administration in children receiving renal replacement therapy. , 2004, , 545-565.		3

#	ARTICLE	IF	CITATIONS
633	Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. <i>Transplant International</i> , 2004, 17, 609-616.	0.8	42
634	Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 993-1004.	0.6	8
635	Drug Use and Dosage in Renal Failure. , 2008, , 991-1002.		2
636	Therapeutic Drugs and Their Management. , 2012, , 1057-1108.		3
637	Immunosuppressive Drugs. , 2013, , 941-956.e4.		2
638	Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 150, 105370.	1.9	12
639	Immunosuppressant drugs - the role of therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 61-73.	1.1	15
640	Measurement of Mycophenolate Mofetil Plasma Levels After Heart Transplantation and a Potential Side Effect of High Levels. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 325.	1.0	11
641	Area Under the Plasma Concentrationâ€“Time Curve for Total, But Not for Free, Mycophenolic Acid Increases in the Stable Phase After Renal Transplantation: A Longitudinal Study in Pediatric Patients. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 498.	1.0	105
642	Pharmacokinetics and Concentration-Control Investigations of Mycophenolic Acid in Adults After Transplantation. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 14-19.	1.0	114
643	Pharmacokinetic and Metabolic Investigations of Mycophenolic Acid in Pediatric Patients After Renal Transplantation: Implications for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 20-26.	1.0	171
644	Development and Application of a High-Performance Liquid Chromatography-Based Assay for Determination of the Activity of Inosine 5-Â-Monophosphate Dehydrogenase in Whole Blood and Isolated Mononuclear Cells. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 283-294.	1.0	37
645	MYCOPHENOLATE MOFETIL AND CYCLOSPORINE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC BLOOD STEM CELL TRANSPLANTATION. <i>Transplantation</i> , 1999, 67, 499-504.	0.5	99
646	THE IMPACT OF ROUTINE MYCOPHENOLATE MOFETIL DRUG MONITORING ON THE TREATMENT OF CARDIAC ALLOGRAFT REJECTION. <i>Transplantation</i> , 2000, 69, 2326-2330.	0.5	77
647	How Delayed Graft Function Impacts Exposure to Mycophenolic Acid in Patients After Renal Transplantation. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 155-164.	1.0	17
648	Nonsteroidal Anti-Inflammatory Drugs May Reduce Enterohepatic Recirculation of Mycophenolic Acid in Patients With Childhood-Onset Systemic Lupus Erythematosus. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 658-662.	1.0	14
649	Drug Interactions Involving Immunosuppressive Agents. <i>Graft: Organ and Cell Transplantation</i> , 0, 4, 232-247.	0.0	7
650	Management of Hyperlipidemia in the Stable Solid Organ Transplant Recipient. <i>Graft: Organ and Cell Transplantation</i> , 0, 4, 266-275.	0.0	6

#	ARTICLE	IF	CITATIONS
651	Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience. <i>Annals of Transplantation</i> , 2017, 22, 707-718.	0.5	7
652	Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. <i>Journal of Zhejiang University Science B</i> , 2005, 6B, 885-891.	0.4	18
653	Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, S1-S86.	3.0	514
654	Effect of uridine diphosphate-glucuronosyltransferase polymorphisms on the plasma concentrations of mycophenolic acid in Turkish renal transplant patients. <i>Å°stanbul TÄ±p FakÅ¼ltesi Dergisi</i> , 2017, 80, 104-110.	0.1	2
655	Why We Need Proper PBPK Models to Examine Intestine and Liver Oral Drug Absorption. <i>Current Drug Metabolism</i> , 2012, 14, 57-79.	0.7	14
656	The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients. <i>Kidney Research and Clinical Practice</i> , 2020, 39, 479-486.	0.9	2
658	Development and validation of limited sampling strategy equation for mycophenolate mofetil in children with systemic lupus erythematosus. <i>Indian Journal of Nephrology</i> , 2016, 26, 408.	0.2	5
659	Generics in transplantation medicine: Randomized comparison of innovator and substitution products containing mycophenolate mofetil. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2019, 57, 506-519.	0.3	7
660	Limited Sampling Strategy for Estimating Area under the Concentration Curve for Mycophenolic Acid in Renal Transplant Recipients with Co-administration of Tacrolimus.. <i>Iryo Yakugaku (Japanese Journal)</i> Tj ETQq0 0 OrqBT /Overlock 10 T		
661	SLCO1B3 polymorphisms and clinical outcomes in kidney transplant recipients receiving mycophenolate. <i>Pharmacogenomics</i> , 2021, 22, 1111-1120.	0.6	1
662	Inosine monophosphate dehydrogenase inhibition: mycophenolate mofetil. , 2001, , 77-96.		0
663	Mycophenolate Mofetil and Azathioprine. , 2001, , 85-110.		0
664	4. Mycophenolate Mofetil. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2005, 36, 63-68.	0.1	2
665	A comparison of the effect of cyclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2006, .	1.1	0
666	Traitement mÃ©dicamenteux de la greffe. , 2008, , 1247-1270.		0
667	Immunoregulatory Drugs. , 2009, , 909-927.		1
668	Micophenolat Mofetil Versus Azathioprine: Effects on Renal Graft Function in Early Posttransplant Period. <i>Bosnian Journal of Basic Medical Sciences</i> , 2009, 9, 156-160.	0.6	2
669	Drug Disposition and Drug Drug Interactions: Importance of First-Pass Metabolism in Gut and Liver. , 2010, , 415-435.		1

#	ARTICLE	IF	CITATIONS
671	Clinical Pharmacologic Principles and Immunosuppression. , 2011, , 87-109.		0
673	Evidence-based Pharmaceutical Care with Immunosuppressants Using Therapeutic Drug Monitoring in Clinical Practice. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2011, 37, 277-287.	0.0	0
675	Influence des immunosuppresseurs co-administrés au mycophénolate mofetil lors du dosage de l'acide mycophénolique par technique immuno-enzymatique. Toxicologie Analytique Et Clinique, 2011, 23, 147-153.	0.1	0
676	Non-HIV Antiviral Agents. , 2011, , 471-508.		0
677	Drug Administration and Pharmacogenomics in Children Receiving Acute or Chronic Renal Replacement Therapy. , 2012, , 609-627.		0
678	Mycophenolic Acid Absorption Profiles in Patients with Kidney or Combined Pancreas-Kidney Transplantation. Open Journal of Nephrology, 2012, 02, 116-122.	0.0	0
679	Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Moller-Ladner (Hrsg.): Klinische Immunologie. , 2012, , e1-e80.		0
682	Special Populations. , 2019, , 219-247.		0
683	Effects of an Ex Vivo Pediatric Extracorporeal Membrane Oxygenation Circuit on the Sequestration of Mycophenolate Mofetil, Tacrolimus, Hydromorphone, and Fentanyl. Journal of Pediatric Pharmacology and Therapeutics, 2019, 24, 290-295.	0.3	6
684	Mycophenolate Mofetil Overdose Induced Ventricular Tachycardia in a Patient with Systemic Lupus Erythematosus. Korean Journal of Medicine, 2019, 94, 455-458.	0.1	0
685	Pharmacogenomics of Immunosuppressants. , 2020, , 83-106.		0
686	Lack of concordance between EMIT assay and LC-MS/MS for Therapeutic Drug Monitoring of Mycophenolic Acid: Potential increased risk for graft rejection?. Journal of Pharmaceutical and Biomedical Analysis, 2020, 187, 113337.	1.4	3
687	Effect of conversion from azathioprine to mycophenolate mofetil on renal function in stable kidney transplant recipients. Turkish Journal of Internal Medicine, 2019, 1, 21-25.	0.3	0
688	Development and validation of an ultra-performance liquid chromatography mass spectrometry/mass spectrometry method for simultaneous quantification of total and free mycophenolic acid and its metabolites in human plasma. Journal of Advanced Pharmaceutical Technology and Research, 2020, 11, 207.	0.4	2
690	Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipientâ€”No Intervention Actually Needed. Transplantation Direct, 2020, 6, e609.	0.8	0
691	The emergence of mycophenolate mofetil in dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room. Journal of Clinical and Aesthetic Dermatology, 2011, 4, 18-27.	0.1	5
692	A review on therapeutic drug monitoring of immunosuppressant drugs. Iranian Journal of Basic Medical Sciences, 2011, 14, 485-98.	1.0	35
693	Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation. Annals of Gastroenterology, 2015, 28, 366-373.	0.4	44

#	ARTICLE	IF	CITATIONS
694	Mycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report. , 2021, 4, .		1
695	Serum albumin level is associated with mycophenolic acid concentration in children with idiopathic nephrotic syndrome. European Journal of Pediatrics, 2022, 181, 1159-1165.	1.3	3
696	Estimation of Mycophenolic Acid Exposure in Heart Transplant Recipients by Population Pharmacokinetic and Limited Sampling Strategies. Frontiers in Pharmacology, 2021, 12, 748609.	1.6	1
697	The Role of Uptake and Efflux Transporters in the Disposition of Glucuronide and Sulfate Conjugates. Frontiers in Pharmacology, 2021, 12, 802539.	1.6	34
698	Is the failure of recent trials on withdrawal of calcineurin inhibitors due to inadequate mycophenolic acid dosing?. Journal of Nephrology, 2022, , 1.	0.9	0
699	Recent lessons learned from population pharmacokinetic studies of mycophenolic acid: physiological, genomic, and drug interactions leading to the prediction of drug effects. Expert Opinion on Drug Metabolism and Toxicology, 2022, , 1-38.	1.5	4
700	Pharmacokinetics of mycophenolic acid and external evaluation of two limited sampling strategies of drug exposure in patients with juvenile systematic lupus erythematosus. European Journal of Clinical Pharmacology, 2022, 78, 1003-1010.	0.8	3
701	Current Treatment of Myasthenia Gravis. Journal of Clinical Medicine, 2022, 11, 1597.	1.0	35
702	Immunosuppression Therapy in Kidney Transplantation. Urologic Clinics of North America, 2022, 49, 345-360.	0.8	4
704	Drug Interactions with Commonly used Immunosuppressive Agents. , 0, , 522-536.		0
705	Short-term treatment with mycophenolic acid increases bile flow in continuously perfused and cold-preserved rat livers and does not affect hepatic ischemia-reperfusion injury. Transplant International, 2002, 15, 265-71.	0.8	1
706	Mycophenolate mofetil and mycophenolic acid. , 2013, , 190-198.e3.		4
707	Application of a gutâ€œliver-on-a-chip device and mechanistic modelling to the quantitative <i>in vitro</i> pharmacokinetic study of mycophenolate mofetil. Lab on A Chip, 2022, 22, 2853-2868.	3.1	18
708	The pharmacogenetics of mycophenolate mofetil in Tunisian renal transplant patients. Personalized Medicine, 2022, 19, 383-393.	0.8	1
709	Use of Pharmacogenetics to Optimize Immunosuppressant Therapy in Kidney-Transplanted Patients. Biomedicines, 2022, 10, 1798.	1.4	9
710	Noncompartmental pharmacokinetics of three intravenous mycophenolate mofetil concentrations in healthy Standardbred mares. Veterinary Dermatology, 2023, 34, 222-234.	0.4	2
711	Immunomodulatory treatment of interstitial lung disease. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662211170.	1.0	15
712	Effect of Meal Timings and Meal Content on the AUC _{0â€œ12h} of Mycophenolic Acid: A Simulation Study. Clinical Pharmacology in Drug Development, 0, , .	0.8	0

#	ARTICLE	IF	CITATIONS
713	Activity Screening of Fatty Acid Mimetic Drugs Identified Nuclear Receptor Agonists. International Journal of Molecular Sciences, 2022, 23, 10070.	1.8	2
714	Therapeutic Drug Monitoring and Toxicology: Relevance of Measuring Metabolites. , 2022, , 197-232.		0
715	Gut Microbiota, the Potential Biological Medicine for Prevention, Intervention and Drug Sensitization to Fight Diseases. Nutrients, 2022, 14, 4220.	1.7	4
716	Influence of Calcineurin Inhibitors and Genetic Polymorphism of Transporters on Enterohepatic Circulation and Exposure of Mycophenolic Acid in Chinese Adult Renal Allograft Recipients. Journal of Clinical Pharmacology, 2023, 63, 410-420.	1.0	1
717	Two cases of a pharmacokinetic interaction between (val)acyclovir and mycophenolate mofetil. Clinical Infection in Practice, 2023, 17, 100211.	0.2	1
718	Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis. Journal of Pharmaceutical Health Care and Sciences, 2023, 9, .	0.4	4
719	The use of mycophenolate mofetil in interstitial lung diseases associated with rheumatic diseases. Clinical Medicine and Pharmacology, 2023, 8, 13-19.	0.1	0
720	Impact of Fasting Status and Circadian Variation on the Pharmacokinetics of Mycophenolate Mofetil and the Glucuronide Metabolite in Renal Transplant Recipients. Transplantation Direct, 2023, 9, e1448.	0.8	0
721	Utilizing therapeutic drug monitoring to optimize therapy with eculizumab and mycophenolate mofetil in a child with C3 glomerulonephritis. Pediatric Nephrology, 2023, 38, 3483-3487.	0.9	2
724	Perspectives on Mycophenolate Mofetil in the Management of Autoimmunity. Clinical Reviews in Allergy and Immunology, 2023, 65, 86-100.	2.9	2
725	Pharmacogenomics of immunosuppressants. , 2023, , 323-344.		0
731	Quantification of Mycophenolic Acid in Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Methods in Molecular Biology, 2024, , 329-336.	0.4	0